Production of substance by strain
By creating a combinatorial library of promoters for bacterial strains, the method addresses the challenge of producing complex biologically active molecules by optimizing gene expression in Bacillus subtilis, achieving high-yield and controlled production of valuable natural products.
Patent Information
- Application Number
- PCT/JP2024/020950
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-09
- Filing Date
- 2024-06-07
- Publication Date
- 2024-12-12
AI Technical Summary
Current methods struggle to efficiently produce complex biologically active molecules like polyketides and non-ribosomal peptides due to the complexity of their biosynthetic gene clusters, which are difficult to engineer and express, limiting the production of valuable natural products in bacterial strains.
A method involving the creation of a combinatorial library of promoters for each gene in a bacterial strain, allowing for monocistronic transcriptional control of gene clusters, which enables the efficient production of target substances by optimizing promoter arrangements and reducing the need for restriction enzyme recognition sequences, facilitating the use of Bacillus subtilis as a host for producing these molecules.
This approach allows for the production of target substances at high levels with desired properties, such as high yield, controlled secretion, and reduced impurities, enabling the efficient generation of biologically active molecules that are difficult to produce through chemical synthesis.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure JPOXMLDOC01-APPB-T000003
Abstract
Description
Substance production by the strain
[0001] The present disclosure relates to the production of substances from strains that exhibit desirable properties.
[0002] Approximately half of the pharmaceuticals developed and used by humans to date are natural products or substances derived from natural products (Non-Patent Document 1). It was previously assumed that the number of natural products available to humans had reached a plateau. However, genome sequencing of microorganisms has revealed that a large amount of unused natural products still remains in the genomes of microorganisms, most of which are not produced under normal laboratory conditions (dormant) or are produced in extremely small amounts and therefore undetectable (Non-Patent Document 2). If we could forcibly activate the biosynthetic gene clusters of these natural products and efficiently produce them, we could expect to obtain novel substances that have not been obtained before, or to efficiently obtain useful substances.
[0003] Among natural products, polyketides (PKs) and nonribosomal peptides (NRPs) are a group of natural products produced by a variety of microbial species, including actinomycetes, filamentous fungi, and Bacillus subtilis. These natural products include many molecules with physiological activities useful to humans, such as antibiotic and anticancer activities. However, their molecular structures are extremely complex, and therefore commercial production by chemical synthesis is impossible or difficult for the majority of them. In other words, biological production methods are required for their industrial use. The gene clusters of polyketide synthases (PKSs) or nonribosomal peptide synthetases (NRPSs) contained in the genomes of microorganisms are generally very long and contain abundant repeat sequences, high GC content, high AT content, etc., making them DNA sequences difficult to synthesize using conventional methods.
[0004] Therefore, constructs have been constructed by cloning from the genome of a target microorganism and transferring them into a target vector, replacing regulatory elements, etc., and using them for homologous or heterologous production. As an example, it has been reported that production yields have been increased by substituting a promoter stronger than the wild type using techniques such as yeast homologous recombination (Non-Patent Document 3) and CRISPR-Cas9 (Non-Patent Document 4, Patent Document 1).
[0005] However, due to the complexity of gene cluster sequences, there are significant constraints on sequence engineering. Furthermore, in many wild-type PKSs and NRPSs, a single promoter generally controls the transcriptional activation of multiple constituent genes or the entire gene cluster. In the case of dormant gene activation or heterologous production, if transcription could be controlled monocistronically on a gene-by-gene basis, and proteins derived from each gene could be transcribed and translated at the appropriate time during the microbial growth period, it would be expected to be effective in increasing production yields. However, for the reasons mentioned above, this has been difficult to achieve with conventional technology.
[0006] KR102301301B1
[0007] D. J. Newman, et. al. , J. Nat. Prod. , 83, 770 (2020) C. C. Brett, et. al. , Annu. Rev. Biochem. , 90, 763 (2021) Kang H-. S. , etc. al. , ACS Synth. Biol. , 5(9), 1002 (2016) Kim H. , etc. al. , ACS Synth. Biol. , 9(1), 175 (2020)
[0008] From the above perspectives, the present disclosure has been completed, which relates to the production of a target substance in a host cell such as Bacillus subtilis by monocistronic transcription of each gene constituting a natural product biosynthetic enzyme gene cluster using a growth-phase-dependent promoter with appropriate transcription strength. That is, the gist of the present disclosure is as follows: (Item X1) A method for producing a strain having desired properties, the method comprising: 1) providing a construct comprising a gene cluster and multiple promoters; 2) creating a combinatorial library of the promoters in the construct; and 3) selecting a strain having the desired properties in a host cell. (Item X1-1) The method according to any one of the above items, wherein the gene cluster comprises multiple genes. (Item X1-2) The method according to any one of the above items, wherein the promoter is operably linked to the gene. (Item X1-3) The method according to any one of the above items, wherein 1) comprises the step of providing a construct comprising a gene cluster comprising multiple genes, wherein the multiple promoters have been introduced. (Item X2) The method according to any one of the above items, wherein the multiple promoters are arranged in a monocistronic configuration for each gene included in the gene cluster, in a polycistronic configuration for all genes in the gene cluster, or in a mixture of monocistronic and polycistronic configurations for the genes in the gene cluster.(Item X3) The method according to any one of the preceding items, wherein the strain having the desired properties has at least one or more properties selected from the following: the ability to produce a target substance, the ability to highly produce a target substance, the ability to retain a target substance within the bacterial cell and not secrete it, the ability to secrete a target substance outside the bacterial cell, the ability to be easily cultured while producing a target substance, the ability to produce multiple target substances in a desired ratio, the ability to produce a target substance without producing harmful substances, the ability to produce a robust amount of a target substance, the ability to prevent defects in a gene that produces a target substance during the culture period, the ability to control the production of a target substance, the ability to suppress the production of substances other than the target substance, the ability to suppress the production of by-products and / or impurities that are difficult to separate by affinity, ion exchange, gel filtration, reverse-phase, normal-phase, chiral chromatography, distillation, crystallization, or the like, the ability to produce a small amount of empty capsids in viral vector production, and the ability to prevent defects in a plasmid. (Item X3-1) The method according to any one of the above items, wherein the empty capsid rate is 80% or less, preferably 70% or less, more preferably 60% or less... 50% or less, 40% or less, 30% or less, 20% or less, 10% or less, and most preferably 0%. (Item X4) A method of carrying out an action based on a desired property using a strain produced by the method according to any one of the above items. (Item X4-1) The method according to any one of the above items, wherein the action includes carrying out an action subsequent to the following property:・The property of being able to produce a target substance: the act of producing a target substance ・The property of producing a high amount of a target substance: the act of producing a target substance ・The property of retaining a target substance within the bacterial cell and not secreting it: the act of producing a target substance and recovering it from within the bacterial cell ・The property of secreting a target substance outside the bacterial cell: the act of producing a target substance and recovering it from the culture medium ・The property of being easy to cultivate with the production of a target substance: the act of producing a target substance under general cultivation conditions ・The property of being able to produce multiple target substances in desired ratios: the act of producing multiple types of target substances ・The property of producing a target substance without producing harmful substances: the act of producing a target substance without using special protective equipment ・The property of having a robust production amount of a target substance: the act of always producing a target substance at a constant ratio ・The property of not causing defects in the gene that produces the target substance during the cultivation period: the act of producing a target substance using a strain that does not have gene defects ・The property of being able to control the production of a target substance: the act of producing a target substance under desired conditions (production amount, type and ratio of derivatives)・A property that can suppress the production of substances other than the target: an act of producing only the target substance ・By-products that are difficult to separate by affinity, ion exchange, gel filtration, reverse phase, normal phase, chiral chromatography, distillation, crystallization, etc. ・A property that can suppress the production of impurities: an act of producing only a substance having a target structure (without producing derivatives) ・A property that reduces the amount of empty capsids produced in viral vector production: an act of producing viral capsids carrying a nucleic acid of interest ・A property that prevents deletion of plasmids: an act of recovering a plasmid having a sequence of interest (Item X5) The method according to any one of the above items, further comprising: 4) creating a combinatorial library of constructs of one or more strains selected in step 3) and introducing the library into a host cell of interest, and 5) performing step 3 again. (Item X5-1) The method according to any one of the above items, wherein the creation of a combinatorial library comprises constructing a combinatorial plasmid library in which promoter sequence portions in plasmids are shuffled.(Item X6) A method for producing a substance in a host organism, the method comprising: (A) constructing a construct in which a promoter introduction site and a sequence for reconstruction are added to a group of genes involved in the production of the substance from which undesired restriction enzyme recognition sequences have been eliminated; (B) introducing multiple types of constructs in which a promoter has been introduced into the promoter introduction site into a host organism for creating a combinatorial library; and (C) Combi-OGAB. TM (D) culturing a host organism for production having the constructs in the combinatorial library and selecting a plurality of strains based on an arbitrary criterion; (E) substituting the promoter sites in the constructs of the plurality of strains for the Combi-OGAB. TM (A) generating a combinatorial library again by the method described above; and (B) producing a substance using a strain having desired properties. (Item X7) The method according to any one of the above items, wherein the host organism used for generating a combinatorial library and the host organism used for production are the same. (Item X8) The method according to any one of the above items, wherein the host organism used for generating a combinatorial library and the host organism used for production are different. (Item X9) The method according to any one of the above items, wherein the host organism is Bacillus subtilis. (Item X10) A method for producing a substance in a host organism, the method comprising the step of producing the substance with a strain produced according to the method described in any one of the above items. (Item X11) A method for producing a substance in a host organism, the method comprising the step of producing the substance with a strain obtained by steps (A) to (E) of the method described in any one of the above items. (Item X12) The method according to any one of the above items, further comprising modifying the strain. (Item X13) The method according to any one of the above items, comprising a step of repeating steps (D) and (E) multiple times. (Item X14) The construction of the construct in step (A) is carried out using OGAB. TMThe method according to any one of the above items, wherein the promoter is carried out by a method. (Item X15) The method according to any one of the above items, wherein the promoters are multiple promoters differing from one another in transcription initiation time and / or transcription strength. (Item X16) The method according to any one of the above items, wherein the host organism for production is Bacillus subtilis, actinomycetes, filamentous fungi, yeast, hydrogen bacterium, coryneform bacteria, or animal cells. (Item X17) The method according to any one of the above items, wherein the host organism is Bacillus subtilis. (Item X18) The method according to any one of the above items, wherein the undesired restriction enzyme recognition sequence is a Type IIS restriction enzyme recognition sequence selected from the group consisting of AarI, BsaI, BbsI, BsmBI, and BspQI, and an SfiI recognition sequence for reconstruction. (Item X19) The method according to any one of the above items, wherein the sequence for reconstruction is an SfiI recognition sequence. (Item X20) The method according to any one of the preceding items, wherein the gene cluster is a gene cluster of polyketide synthase (PKS) and non-ribosomal peptide synthase (NRPS).
[0009] The gist of the present disclosure is further as follows: (Item 1) A method for producing a strain having desired properties, the method comprising the steps of: 1) providing a construct containing a gene cluster containing multiple genes, wherein the construct has multiple promoters introduced therein; 2) creating a combinatorial library of the promoters in the construct; and 3) selecting a strain having the desired properties in a host cell. (Item 2) The method according to the above item, wherein the multiple promoters are arranged in a monocistronic manner. (Item 3) The method according to any one of the above items, wherein the strain having the desired property has at least one characteristic selected from the group consisting of: a strain capable of producing a target substance, a strain that highly produces the target substance, a strain that retains the target substance intracellularly and does not secrete it, a strain that secretes the target substance extracellularly, a strain that produces a target substance that is easy to cultivate, a strain that can produce multiple target substances in desired ratios, a strain that produces a target substance without producing harmful substances, a strain that produces a robust amount of the target substance, a strain that does not develop defects in the gene that produces the target substance during the culture period, a strain that can control the production of the target substance, a strain that can suppress the production of non-target substances, a strain that can suppress the production of by-products that are difficult to separate by affinity, ion exchange, gel filtration, reverse phase, normal phase, chiral chromatography, distillation, crystallization, etc., and impurities, a strain that produces a low amount of empty capsids in viral vector production, and a strain that does not develop defects in the plasmid. (Item 4) A method for performing an action based on a desired property using a strain produced in any one of the above items. (Item 5) The method according to any of the above items, further comprising: 4) creating a combinatorial library of constructs from one or more strains selected in step 3) and introducing the library into a host cell of interest; and 5) repeating step 3).(Item 6) A method for producing a substance in a host organism, the method comprising: (A) constructing a construct in which a promoter introduction site and a sequence for reconstruction are added to a group of genes involved in the production of the substance from which undesired restriction enzyme recognition sequences have been eliminated; (B) introducing multiple types of constructs in which a promoter has been introduced into the promoter introduction site into a host organism for creating a combinatorial library; and (C) Combi-OGAB. TM (D) culturing a host organism for production having the constructs in the combinatorial library and selecting a plurality of strains based on an arbitrary criterion; (E) substituting the promoter sites in the constructs of the plurality of strains for the Combi-OGAB. TM (A) a step of constructing a combinatorial library again by the method described above; and (B) a step of producing a substance using a strain having desired properties. (Item 7) The method described in any of the above items, wherein the host organism used for constructing a combinatorial library and the host organism used for production are the same. (Item 8) The method described in any of the above items, wherein the host organism used for constructing a combinatorial library and the host organism used for production are different. (Item 9) The method described in any of the above items, wherein the host cell is Bacillus subtilis. (Item 10) A method for producing a substance in a host organism, the method comprising the step of producing the substance with a strain produced according to the method described in any of the above items. (Item 11) A method for producing a substance in a host organism, the method comprising the step of producing the substance with a strain obtained by steps (A) to (E) of the method described in any of the above items. (Item 12) The method described in any of the above items, further comprising modifying the strain. (Item 13) The method according to any one of the above items, comprising a step of repeating steps (D) and (E) multiple times. (Item 14) The construction of the construct in step (A) is carried out by using OGAB. TM(Item 15) The method according to any of the above items, wherein the promoters are different from one another in transcription initiation time and / or transcription strength. (Item 16) The method according to any of the above items, wherein the host organism for production is Bacillus subtilis, actinomycetes, filamentous fungi, yeast, hydrogen bacterium, coryneform bacteria, or animal cells. (Item 17) The method according to any of the above items, wherein the host organism is Bacillus subtilis. (Item 18) The method according to any of the above items, wherein the undesired restriction enzyme recognition sequence is a Type IIS restriction enzyme recognition sequence selected from the group consisting of AarI, BsaI, BbsI, BsmBI, and BspQI, and an SfiI recognition sequence for reconstruction. (Item 19) The method according to any of the above items, wherein the sequence for reconstruction is an SfiI recognition sequence. (Item 20) The method according to any one of the above items, wherein the gene cluster is a gene cluster of polyketide synthase (PKS) and non-ribosomal peptide synthase (NRPS).
[0010] According to one embodiment of the present disclosure, various restriction enzymes can be used to transcriptionally activate a desired gene group, such as a natural product biosynthetic enzyme gene group, in monocistronic units, and to create a combinatorial library of promoters for each gene, thereby running a screening cycle. In one embodiment of the present disclosure, for long and complex sequences such as natural product biosynthetic enzyme gene groups, the only method used until now has been to clone them from the genome of the target microorganism. However, removing the restriction enzyme recognition sequences one by one is a very time-consuming and costly task, but this can be easily achieved, allowing the screening cycle to run. In one embodiment of the present disclosure, applications such as adding a new gene pathway to a natural biosynthetic system, or using a gene group related to biopharmaceutical synthesis or sequence optimization of an AAV vector, which often contain long and complex sequences, can also be easily performed in such cases.
[0011] In one embodiment of the present disclosure, OGAB TM The method can be used, which is an innovative technique for assembling a large number of DNA fragments and synthesizing long-chain DNA. In one application of one embodiment of the present disclosure, this technique can be used to construct a long-chain gene cluster designed on a computer from which the above-mentioned restriction enzyme recognition sequences have been removed. In one application of one embodiment of the present disclosure, OGAB TM By using this method, promoters are not included during construction, and promoter insertion sites can be incorporated into the design so that promoters can be introduced later. By using this strategy, it is possible to construct OGAB without the need to accumulate a large number of DNA fragments for each plasmid (seed plasmid) into which a promoter has been introduced, which will serve as the seed for the combinatorial library. TM A promoter can be introduced into a plasmid constructed by this method. Furthermore, even if a specific promoter species is desired to be added based on experimental results, a seed plasmid can be easily prepared, and such an advantage can also be applied in one embodiment of the present disclosure.
[0012] In the production of a target substance, the target substance, intermediates in metabolic processes, proteins produced by constituent genes, etc. may affect the growth of the host organism (e.g., antibiotics, cytotoxicity, etc.). In such cases, adjusting production to occur during the late growth phase is expected to acquire self-resistance and allow substance production to occur (Reference 5). It is impossible to predict which growth phase and transcription strength of each gene constituting a gene cluster will be appropriate for producing the target substance. However, in one embodiment of the present disclosure, a combinatorial library of growth phase-dependent promoters with different intensities, in addition to promoters that exhibit constitutive transcriptional activity, is constructed for each gene, and screening is performed using production volume as an indicator to obtain strains with the best promoter combination.
[0013] Bacillus subtilis is used in one embodiment of the present disclosure. This bacterium is a microorganism that naturally produces NRPS such as surfactin and plipastatin, and has high potential as a host for producing natural products. TM This method can utilize Bacillus subtilis, and by using this and introducing a growth phase-dependent promoter (Reference 6) of Bacillus subtilis, the Bacillus subtilis used for accumulating a gene group into which a promoter has been introduced can be directly used for substance production, thereby eliminating steps such as plasmid extraction and host transformation, and enabling strains that produce the desired substance to be obtained quickly.
[0014] According to the present disclosure, it is possible to rapidly and efficiently obtain strains that exhibit desired properties. The present disclosure also provides a method for producing microbial strains that exhibit desired properties, such as high production and by-product suppression, by activating a desired gene cluster, such as genes constituting a gene cluster for natural product biosynthetic enzymes, and potentially novel substances that can be obtained thereby.
[0015] Figure 1 shows the structure of the integration plasmid vector pGETS151 deltaBsmB I-pBR. Figure 2 shows the plasmid used in Example 1, into which Triketide Pyrone BGC was integrated. Figure 3 shows the structure of Combi-OGAB. TM Figure 4 shows how the production volume of Pyrone-OMe converges according to the cycle. TM Figure 5 shows the state in which the methylation efficiency by BpsB improves and converges according to the cycle. Figure 6 shows the plasmid in which GramicidinS BGC was accumulated, used in Example 2. TM 7 shows the chromatogram of the strain producing the by-product Gramicidin S among the strains in the first cycle. TM 8 shows the convergence of the amount of Gramicidin S produced according to the cycle. Fig. 8 shows the spectrum of the product of the strain that produces a by-product of Gramicidin S, analyzed by LC-MS.
[0016] The present disclosure will now be described with reference to the best mode. Throughout this specification, singular expressions should be understood to include the plural concept unless otherwise specified. Therefore, singular articles (e.g., "a," "an," "the," etc. in English) should be understood to include the plural concept unless otherwise specified. Furthermore, it should be understood that terms used in this specification are used in the sense commonly used in the art unless otherwise specified. Therefore, unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. In the event of conflict, the present specification (including definitions) will prevail.
[0017] The following provides definitions of terms particularly used in this specification and / or explains basic technical content as appropriate.
[0018] As used herein, the term "monocistronic" refers to a single promoter being arranged for a single gene, whereas the term "polycistronic" refers to a single promoter being arranged for multiple genes.
[0019] As used herein, the term "combinatorial library creation" refers to the creation of a library by creating a comprehensive combination of multiple substances (e.g., multiple promoters). For example, combinatorial library creation includes the construction of a combinatorial plasmid library in which promoter sequence portions in plasmids are shuffled.
[0020] As used herein, the term "desired properties" refers to properties that are beneficial in substance production. Desired properties include the ability to produce a target substance, the ability to produce a high level of a target substance, the ability to retain the target substance within the bacterial cell and not secrete it, the ability to secrete the target substance outside the bacterial cell, the ability to be easily cultured with the production of a target substance (for example, growing under general culture conditions (medium, temperature, culture time, etc.)), the ability to produce multiple target substances in a desired ratio, the ability to produce a target substance without producing harmful substances (no toxicity, etc.), the ability to produce a robust amount of target substance, the ability to prevent defects in genes that produce the target substance during the culture period, the ability to control the production of a target substance, and the ability to produce substances other than the target substance. Examples of such properties include, but are not limited to, the ability to suppress the production of substances; the ability to suppress the production of by-products and / or impurities that are difficult to separate by affinity, ion exchange, gel filtration, reverse phase, normal phase, chiral chromatography, distillation, crystallization, etc.; the ability to produce a low amount of empty capsids in viral vector production (for example, an empty capsid rate of 80% or less, preferably 70% or less, more preferably 60% or less... 50% or less, 40% or less, 30% or less, 20% or less, 10% or less, and most preferably 0%); and the ability to prevent deletion of the plasmid.
[0021] As used herein, the term "high production of a target substance" refers to a property of producing a higher amount of target substance than a naturally occurring strain. A naturally occurring strain refers to a strain in which a substance-producing gene cluster without sequence engineering (without promoter replacement, etc.) is introduced into a production host (described in claim 16). The property of high production of a target substance can be, but is not limited to, a property of producing a higher amount of target substance than the naturally occurring strain by at least 10%, preferably 20% or more.
[0022] As used herein, the term "ease of culturing resulting in the production of a target substance" refers to the ability of the strain to grow and produce a target substance under culture conditions commonly used for the strain being cultured. For example, the term indicates that the strain can be cultured under common culture conditions, such as 24 hours of shaking culture at 37°C using a medium commonly used for microbial culture, such as LB medium, a non-selective medium, and is not "difficult to cultivate." Furthermore, ease of culturing also includes conditions under which the strain can be cultured in a typical laboratory (BSL1), rather than in a Biosafety Level (BSL) 2 or 3 laboratory, which requires special equipment for handling the strain in terms of pathogenicity, etc.
[0023] As used herein, the term "robust production of a target substance" refers to a highly reproducible property that always shows the same production amount when production is examined. As one method for verifying robustness, for example, the robustness of experimental results can be evaluated by calculation using the Fano factor described in ACS Synth. Biol., 11, 1686-1691. (2022).
[0024] As used herein, the term "the property of not causing gene deficiency" refers to the property of not causing a gene or a part thereof to be defective due to the deletion of all or part of the nucleic acid encoding the gene, nor causing a loss of gene function due to a mutation in part of the nucleic acid encoding the gene.
[0025] As used herein, the term "eliminating an undesired restriction enzyme recognition sequence" refers to deleting an undesired restriction enzyme recognition sequence in the method of the present disclosure, substituting it with another base or sequence, or adding another base or sequence to eliminate the undesired restriction enzyme recognition sequence, or to changing it to a sequence that cannot be recognized by a restriction enzyme. Examples of undesired restriction enzyme recognition sequences include, for example, OGAB. TM DNA synthesis by Combi-OGAB TM The restriction enzymes may be those used in library construction by the method.
[0026] As used herein, the term "promoter introduction site" refers to a site upstream of each gene in a gene cluster where a promoter should be introduced.
[0027] As used herein, the term "sequence for reconstitution" refers to a restriction enzyme recognition sequence for forming an assembled nucleic acid. The assembled nucleic acid formed by cleavage is reconstituted to generate a circular plasmid.
[0028] As used herein, "OGAB TM The "Ordered Gene Assembly in Bacillus subtilis" method or "multiple DNA fragment assembly method using Bacillus subtilis" refers to a method for generating circular plasmids in a transformed organism by incorporating assembled nucleic acids into the organism. TM The method can use any organism that can take up non-circular long chain nucleic acids and produce plasmids, and such organisms are referred to herein as "transformed organisms." TM In this method, a plasmid containing a large nucleic acid can be easily prepared. The nucleic acid to be introduced into a transformed organism is referred to as an "integrated nucleic acid" in this specification. Typically, the integrated nucleic acid has a tandem repeat structure in which one unit of the plasmid and one set of unit nucleic acids appear repeatedly in the same direction. The use of an integrated nucleic acid with such a structure can promote the production of a plasmid in a transformed organism.
[0029] As used herein, "Combi-OGAB" TM "Combinatorial OGAB TM "Combinatorial library construction method using Bacillus subtilis" refers to a method of constructing a combinatorial library using Bacillus subtilis by mixing nucleic acids collected from multiple constructs in a B. subtilis strain. TM This refers to a method for creating a combinatorial library by reconstructing nucleic acid units into combinations using the OGAB method. See also Patent No. 7101431. TM " and "Combi-OGAB TM " is a trademark of the applicant.
[0030] As used herein, the term "actinomycetes" refers to a general group of Gram-positive bacteria that exhibit the morphological characteristic of growing elongated cells that form hyphae, and includes many genera in the phylum Actinobacteria, as well as some bacilli and cocci, which are classified based on molecular phylogeny using the base sequence of the 16Sr ribonucleic acid (RNA) gene.
[0031] As used herein, the term "filamentous fungi" refers to fungi that form hyphae and grow by spores, commonly known as molds.
[0032] As used herein, "polyketide synthase (PKS)" refers to a multidomain enzyme or enzyme complex that synthesizes polyketides. It is found in eubacteria, fungi, plants, and a few animals. There are three types of PKS: type I, type II, and type III. Type I PKSs are long proteins with multiple domains linked together on a single polypeptide; type II PKSs are complexes of proteins with different functions; and type III polyketide synthases are small proteins consisting of only a ketosynthase domain. All of these enzymes catalyze the multiple condensation of extended-chain substrates (such as malonyl-CoA) with CoA esters (or ACP forms) known as starter substrates. Commonly used starter substrates include acetyl-CoA, fatty acid CoA esters, benzoyl-CoA, and coumaroyl-CoA.
[0033] As used herein, "non-ribosomal peptide synthase (NRPS)" refers to a group of enzymes that synthesize peptides using amino acids as substrates, independently of ribosomes and without the intervention of nucleic acids such as mRNA. NRPSs are actually ultra-large protein complexes with molecular weights of several thousand kDa.
[0034] As used herein, "Bacillus subtilis" refers to any bacterium that is aerobic, Gram-positive, catalase-positive, and present ubiquitously in soil and plants, and in the gastrointestinal tract of ruminants and humans. It is 0.7-0.8 x 2-3 μm in size, mesophilic, and grows optimally at 25-40°C. It is believed to form spores, and is non-pathogenic and naturally transformable, including the scientific name Bacillus subtilis and closely related Bacillus genus bacteria, such as Bacillus amyloliquefaciens, Bacillus licheniformis, and Bacillus pumilus. In a preferred embodiment, the Bacillus subtilis is the Marburg 168 strain, a strain of Bacillus subtilis with high naturally transformability, or its derivative, the RM125 strain. The 168 strain is the most genetically studied Gram-positive bacterium, and is harmless to humans and animals. OGAB is a naturally transformable bacterium. TM The method is known to be applicable and can be suitably used in the present disclosure.
[0035] As used herein, the term "sequence replicated in Bacillus subtilis" is used interchangeably with "sequence amplified in Bacillus subtilis" and refers to a nucleic acid sequence that is replicated (or amplified) when introduced into Bacillus subtilis. Here, in this context, amplification is used synonymously with replication. Replication mechanisms for nucleic acids (plasmids) in Bacillus subtilis include rolling circle, theta, oriC, and phage-based mechanisms, and any of these mechanisms can be used as sequences that are replicated in Bacillus subtilis. The rolling circle replication mechanism is a mechanism in which one single strand of double-stranded DNA is replicated, and then the other strand is replicated; since the nucleic acid remains as single-stranded DNA for a long time, the plasmid tends to become unstable. The theta replication mechanism is a mechanism in which replication of double-stranded DNA (plasmid) is initiated simultaneously in two directions from a replication origin, similar to the replication of bacterial chromosomes, and can be preferably used when replicating long DNA (e.g., 10 kb or more) as in the present disclosure (Janniere, L., A. Gruss, and S.D. Ehrlich. 1993. Plasmids, pp. 625-64. In A. L. Sonenshein, J.A. Hoch, and R. Losick (ed.), Bacillus subtilis and other Gram-positive bacteria: biochemistry, physiology and molecular genetics. American Society for Microbiology, Washington, DC). The replication mechanism of oriC operates in the same manner as in the replication of the host bacterial (e.g., Bacillus subtilis) chromosome. Sequences replicated in B. subtilis include plasmids or parts thereof, replication origins, or variants thereof, known to activate replication mechanisms such as rolling circle, theta, oriC, and phage. Known rolling circle plasmids include pUB110, pC194, pE194, and pT181, and known theta plasmids include pAMβ1, pTB19, pLS32, and pLS20.The sequence replicated in Bacillus subtilis may have a sequence identical or similar to that of a known replication origin (e.g., 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, 99.5% or more sequence identity). For example, if a DNA fragment linking a candidate DNA fragment and a selectable marker gene effective in Bacillus subtilis, such as a drug resistance gene, is introduced into Bacillus subtilis and then cultured (with the addition of a drug or the like), and the DNA fragment is replicated extrachromosomally, it can be determined that the candidate DNA fragment has a sequence replicated in Bacillus subtilis.
[0036] As used herein, "plasmid" refers to a circular DNA that exists separately from chromosomes in a cell or that exists separately from chromosomes when introduced into a cell.
[0037] As used herein, the term "nucleic acid sequence that promotes plasmid replication" is used interchangeably with the term "nucleic acid sequence that promotes plasmid amplification" and refers to any nucleic acid sequence that, when introduced into a host cell (e.g., Bacillus subtilis), promotes the replication (in this context, the same as amplification) of a plasmid present in the host cell. Preferably, but not limited to, this nucleic acid sequence that promotes plasmid replication is operably linked to a nucleic acid sequence encoding a target plasmid. Details of the nucleic acid sequence that promotes plasmid replication, the target plasmid, and their relationship are described elsewhere in this specification. Examples of nucleic acid sequences that promote plasmid replication include nucleic acid sequences containing an origin of replication that operates in the target host cell (e.g., Bacillus subtilis). A nucleic acid sequence that promotes plasmid amplification refers to a DNA fragment that has an origin of replication and can replicate independently of chromosomal DNA. Whether these DNA fragments are replicable can be confirmed by, for example, linking a selectable marker gene such as a drug resistance gene to these DNA fragments, culturing them under selective conditions such as a drug, purifying the plasmid DNA, and observing the DNA band by electrophoresis. In addition to the replication origin, the plasmid may contain a rep protein gene that induces a host DNA replication enzyme at the replication origin, a partitioning mechanism gene for ensuring partitioning of the plasmid into daughter cells, a selection marker gene, etc. The replication origin may be fused within the rep protein gene.
[0038] As used herein, "packaging cells" refers to cells for producing vector plasmids.
[0039] As used herein, the term "vector plasmid" or "viral vector plasmid" refers to a plasmid containing a gene to be carried in the viral vector and used to produce the viral vector in a producer cell. In one embodiment, the vector plasmid contains a sequence of a gene (desired gene) to be expressed in the target cell of the viral vector between two terminal repeat sequences, and may also contain a promoter and other elements (e.g., enhancer, terminator, etc.).
[0040] As used herein, the term "producer cell" refers to a cell capable of producing a desired viral vector, and may be a cell in which genes necessary for viral vector production are expressed from the chromosome and an introduced plasmid. By introducing a vector plasmid of the present disclosure into a producer cell, a desired viral vector can be produced. For example, in the case of an AAV viral vector, E1A and E1B are required for its production, but HEK293 cells possess these, so they can be removed from the helper plasmid. Other cells can also function as producer cells if they are modified to contain such helper factors.
[0041] As used herein, "viral vector" refers to a construct that has at least a partial structure derived from a virus and is capable of introducing nucleic acid into target cells. Typically, viral vectors are in the form of viral particles containing a viral capsid and a nucleic acid containing a heterologous gene. As used herein, "source virus" refers to a virus that naturally possesses the viral-derived structure of the viral vector. In a viral vector, the nucleic acid encapsulated in the capsid (carrying nucleic acid) contains a gene sequence (desired gene) to be expressed in the target cell of the viral vector between two terminal repeat sequences, and may also contain a promoter, enhancer, terminator, etc., or a gene derived from the source virus.
[0042] As used herein, the term "nucleic acid sequence necessary for constructing a viral vector" refers to a nucleic acid sequence (e.g., a combination of nucleic acid sequences) that allows a producer cell containing the nucleic acid sequence to produce a viral vector. In one embodiment, the nucleic acid sequence necessary for constructing a viral vector includes a nucleic acid sequence encoding a viral capsid protein, a nucleic acid sequence encoding a protein that packages, transcribes, and replicates the viral genome, two viral terminal repeats, and a nucleic acid sequence of a helper gene. The "nucleic acid sequence of a helper gene" may include or essentially consist of any nucleic acid sequence necessary for constructing a viral vector other than, for example, a nucleic acid sequence encoding a viral capsid protein, a nucleic acid sequence encoding a protein that packages, transcribes, and replicates the viral genome, and two viral terminal repeats. Each of these nucleic acid sequences may differ depending on the viral vector. Details of these sequences are described elsewhere in this specification. In a preferred embodiment, the nucleic acid sequence necessary for constructing a viral vector utilizes advantageous sequences common to AAV and adenovirus, and more preferably, advantageous sequences for AAV. Such advantageous sequences common to AAV and adenovirus have the characteristic of containing a desired gene between inverted terminal repeats (ITRs) and optionally containing helper genes rep and cap or L1, L2, L3, L4, and L5, while advantageous sequences for AAV have the characteristic of containing a desired gene between ITRs and optionally containing helper genes rep and cap. The helper genes rep and cap may be located outside the two ITRs. Examples of such sequences include, but are not limited to, the sequences of specific helper genes E1A, E1B, E2A, E2B, E3, and E4.
[0043] As used herein, the term "proteins that package, transcribe, and replicate the viral genome" includes proteins that encapsulate the viral genome into a capsid, proteins that transcribe the viral genome, proteins that replicate the viral genome, and proteins that have both functions, and examples thereof include E1A, E1B, E2A, E2B, E4, rep, pol, ψ, APP, MAAP, and rev. Although not intended to be limiting, proteins that package, transcribe, and replicate the viral genome may be derived from any of adenovirus serotypes 1 to 52 or adeno-associated virus serotypes 1 to 12, or variants thereof (rh10, DJ, DJ / 8, PHP.eB, PHP.S, AAV2-retro, AAV2-QuadYF, AAV2.7m8, AAV6.2, rh.74, AAV2.5, AAV-TT, Anc80, etc.). The protein may be naturally occurring or may be artificially mutated.
[0044] As used herein, "capsid" refers to a protein produced from a viral gene present on the surface of a virus or viral vector (optionally enclosed in an envelope), and is also referred to as a "capsid protein." The capsid may be responsible for cell infectivity. Examples of capsid proteins include, but are not limited to, L2, L3, cap, VSV-G, and gag. While not intended to be limiting, nucleic acid sequences encoding viral capsid proteins may be derived from adenovirus serotypes 1 to 52 or adeno-associated virus serotypes 1 to 12, or variants thereof (e.g., rh10, DJ, DJ / 8, PHP.eB, PHP.S, AAV2-retro, AAV2-QuadYF, AAV2.7m8, AAV6.2, rh.74, AAV2.5, AAV-TT, Anc80, etc.). The capsid may be naturally occurring or may be artificially mutated.
[0045] As used herein, the term "repeated sequence" or "tandem repeat" (nucleic acid sequence) refers to a nucleic acid sequence in an organism genome in which the same sequence is found repeatedly (especially several times or more). Any repetitive sequence used in the art can be used in the present disclosure. Typically, a promoter sequence appears repeatedly.
[0046] As used herein, the term "terminal repeat" refers to a nucleic acid sequence in an organism's genome in which the same sequence is repeated (especially several times or more), and is present at the end of the nucleic acid sequence. Examples of terminal repeat sequences include, but are not limited to, inverted terminal repeats (ITRs) or long terminal repeats (LTRs). Terminal repeat sequences may be derived from adenovirus serotypes 1 to 52 or adeno-associated virus serotypes 1 to 12, or variants thereof (rh10, DJ, DJ / 8, PHP.eB, PHP.S, AAV2-retro, AAV2-QuadYF, AAV2.7m8, AAV6.2, rh.74, AAV2.5, AAV-TT, Anc80, etc.). Terminal repeat sequences may be naturally occurring or may be those into which mutations have been artificially introduced.
[0047] As used herein, the term "helper gene" refers to a gene that supports the amplification of a virus that cannot grow on its own. In the present disclosure, helper genes may include, but are not limited to, nucleic acid sequences encoding the capsid proteins of the virus, nucleic acid sequences encoding proteins that package, transcribe, and / or replicate the genome of the virus, and nucleic acid sequences necessary for the construction, growth, activity improvement, and toxicity reduction of any viral vector other than the two terminal repeat sequences of the virus. Examples of helper genes that can be used include, but are not limited to, E1A, E1B, E2A, E2B, E4, RPE, WRPE, PPT, oPRE, enhancer, insulator, silencer sequences, etc.
[0048] As used herein, the term "nucleic acid unit" refers to a nucleic acid molecule or a portion of a nucleic acid molecule having a partial sequence that constitutes the sequence of a nucleic acid assembly. As described in detail elsewhere herein, multiple types of nucleic acid unit molecules are prepared as unit vectors, and then nucleic acid assembly vectors are constructed. The nucleic acid unit molecules of the present disclosure may be DNA, RNA, modified forms thereof, or a mixture thereof. A method for preparing nucleic acid unit molecules or compositions containing the same of the present disclosure includes the steps of: preparing solutions containing multiple nucleic acid unit molecules, each type linked to an additional sequence; and, after preparing each solution, measuring the concentration of the nucleic acid unit molecules in each solution while the additional sequence is still linked to the nucleic acid unit molecules; and, based on the results, aliquoting each solution to adjust the molar number of nucleic acid unit molecules in each solution to be approximately the same. As used herein, the types of "nucleic acid unit" are distinguished by their respective base sequences. Furthermore, "nucleic acid unit" includes both those with and without restriction enzyme recognition sites added. The length of each nucleic acid unit is not particularly limited; however, when confirming the base sequence of a nucleic acid unit, it is preferable to reduce the number of base sequence determinations, as this reduces time and financial costs. Therefore, the length of each nucleic acid unit is preferably short; specifically, 1600 bp or less is preferred, and 1200 bp or less is even more preferred. In particular, when determining base sequences using an automated fluorescent sequencer based on the Sanger method, a base sequence of approximately 800 consecutive bases can be confirmed in a single base sequence determination. Therefore, the length of each nucleic acid unit is most preferably 800 bp or less (specifically, 600 bp or less, 500 bp or less, 400 bp or less, 200 bp or less, 100 bp or less, etc.). Thus, if each nucleic acid unit is short, a large number of nucleic acid units will be required when used to prepare a DNA concatemer, as described below. However, when the nucleic acid unit prepared by the method of the present disclosure is used, a large number of nucleic acid unit units can be concatenated, as described below. Furthermore, if each nucleic acid unit is too short, the number of nucleic acid unit units will increase, resulting in reduced operational efficiency. Therefore, the length of each nucleic acid unit is preferably 20 bp or more, more preferably 30 bp or more, and even more preferably 50 bp or more.The vector DNA and each nucleic acid unit have a structure that allows them to be repeatedly linked to each other while maintaining their order. As used herein, "linked to each other while maintaining their order" refers to nucleic acid unit or vector DNA units having adjacent sequences on the nucleic acid assembly unit being bound to each other while maintaining their order and orientation.
[0049] As used herein, "endotoxin" refers to a toxin that is a component of the cell wall of Gram-positive bacteria such as Bacillus subtilis and is not actively secreted. It can also be quantified using a kit such as the Pierce LAL Endotoxin Quantitation Kit (Thermo Fisher Scientific, USA). "Endotoxin" is present only in Gram-negative bacteria and is not present in Gram-positive bacteria. "Endotoxin" is also called lipopolysaccharide (LPS), which is present in the outer membrane of Gram-negative bacteria and has a structure of O antigen-core polysaccharide-lipid A, of which lipid A is physiologically active. Gram-positive bacteria do not have an outer membrane and therefore do not have lipid A either.
[0050] As used herein, "loaded nucleic acid" refers to a nucleic acid carried by a viral vector. Whether or not a nucleic acid is loaded can be confirmed by treating a viral vector preparation with DNase to degrade nucleic acids outside the capsid, inactivating the DNase, and then examining the nucleic acid extracted from the capsid. Whether or not a nucleic acid is loaded can also be confirmed by examining the sequence of the resulting nucleic acid product (preferably full-length or nearly full-length).
[0051] As used herein, "host cell" refers to a cell (including the progeny of such a cell) into which an exogenous nucleic acid or protein, or virus or viral vector has been introduced.
[0052] As used herein, the terms "protein," "polypeptide," and "peptide" are used interchangeably to refer to a polymer of amino acids of any length. The polymer may be linear, branched, or cyclic. The amino acids may be natural, non-natural, or modified. The term also encompasses naturally or artificially modified polymers. Such modifications include, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification (e.g., conjugation with a labeling component).
[0053] Unless otherwise indicated, a particular nucleic acid sequence is also intended to encompass the explicitly indicated sequence, as well as conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences. Specifically, degenerate codon substitutions can be achieved by creating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues. For example, variants based on specific wild-type sequences, such as adenovirus serotypes 1 to 52 and adeno-associated virus serotypes 1 to 12, include not only known variants (e.g., rhlO, DJ, DJ / 8, PHP.eB, PHP.S, AAV2-retro, AAV2-QuadYF, AAV2.7m8, AAV6.2, rh.74, AAV2.5, AAV-TT, Anc80, etc.), but also nucleic acids comprising a sequence having at least 70%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to the original sequence.
[0054] As used herein, the term "gene" refers to a nucleic acid segment that performs a specific biological function. Examples of such biological functions include encoding a polypeptide or protein, encoding non-protein-coding functional RNA (e.g., rRNA, tRNA, microRNA (miRNA), lncRNA), controlling the production of a polypeptide, protein, or non-protein-coding functional RNA, specifically binding to a specific protein, or controlling nucleic acid cleavage or replication. Therefore, as used herein, "gene" includes not only nucleic acid segments encoding proteins or non-protein-coding functional RNA, but also transcriptional / translational regulatory sequences such as promoters, terminators, enhancers, insulators, silencers, replication origins, and internal ribosome entry sites, as well as nucleic acid segments required for packaging into viral particles. As used herein, "gene product" may refer to a polypeptide, protein, or non-protein-coding functional RNA encoded by a gene.
[0055] When referring to the number of genes herein, one gene refers to a gene having a contiguous sequence in the form that is normally present (highest frequency or probability of 50% or more) in the genome of a certain organism. For example, two exons encoding a certain protein can be two genes. For example, if a promoter sequence and a protein-encoding sequence form a contiguous sequence, the nucleic acid portion including the promoter sequence and the protein-encoding sequence can be one gene. For example, if a protein that becomes functional when cleaved is encoded by a contiguous sequence on the genome, this protein can be encoded by one gene. When referring to a gene from the perspective of function, the nucleic acid sequence does not need to be a contiguous sequence; for example, multiple exons encoding a certain protein can be collectively referred to as the gene for that protein.
[0056] As used herein, "defective" of a gene means that the nucleic acid does not contain the gene or contains a gene that has been altered so that it does not perform the normal function of the gene (e.g., to produce a functional protein).
[0057] As used herein, "operably linked" means that the expression (operation) of a desired sequence is placed under the control of a transcriptional / translational regulatory sequence (e.g., a promoter, an enhancer, etc.) or a translational regulatory sequence. In order for a promoter to be operably linked to a gene, the promoter is usually placed immediately upstream of the gene, but is not necessarily placed adjacent to the gene.
[0058] As used herein, the term "transcriptional / translational regulatory sequence" collectively refers to promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, replication origins, enhancers, IRES, and the like, which cooperate to enable the replication, transcription, and translation of a coding sequence in a recipient cell. Not all of these transcriptional / translational regulatory sequences necessarily need to be present, as long as the selected coding sequence is capable of being replicated, transcribed, and translated in an appropriate host cell. Those skilled in the art can easily identify regulatory nucleic acid sequences from publicly available information. Furthermore, those skilled in the art can identify transcriptional / translational regulatory sequences that are applicable to the intended use, for example, in vivo, ex vivo, or in vitro.
[0059] As used herein, "promoter" refers to a segment of a nucleic acid sequence that controls the transcription of an operably linked nucleic acid sequence. A promoter contains a specific sequence that is sufficient for recognition, binding, and transcription initiation by RNA polymerase. A promoter may also contain a sequence that regulates recognition, binding, or transcription initiation of RNA polymerase.
[0060] As used herein, "enhancer" refers to a segment of a nucleic acid sequence that functions to increase the efficiency of expression of a gene of interest.
[0061] As used herein, the term "silencer" refers to a segment of a nucleic acid sequence that has the function of reducing the expression efficiency of a gene of interest, in contrast to an enhancer.
[0062] As used herein, "insulator" refers to a segment of nucleic acid sequence that has a cis-regulatory function of regulating the expression of genes located at distant positions in the DNA sequence.
[0063] As used herein, "terminator" refers to a segment of nucleic acid sequence located downstream of a protein-coding region and involved in terminating transcription when the nucleic acid is transcribed into mRNA.
[0064] As used herein, the term "origin of replication" refers to a segment of a nucleic acid sequence at which replication is initiated by the binding of a protein that recognizes the nucleic acid sequence (e.g., the initiator DnaA protein) and the synthesis of RNA, thereby partially unwinding the DNA double helix.
[0065] As used herein, an internal ribosome entry site ("IRES") refers to a nucleic acid segment that facilitates the entry or retention of a ribosome during translation of a downstream nucleic acid sequence.
[0066] As used herein, the term "homology" of nucleic acids refers to the degree of identity between two or more nucleic acid sequences, and generally, "homology" refers to a high degree of identity or similarity. Therefore, the higher the homology between two nucleic acids, the higher the identity or similarity between their sequences. "Similarity" is a numerical value that takes into account not only identity but also similar bases, where similar bases refer to partial matches in mixed bases (e.g., R = A + G, M = A + C, W = A + T, S = C + G, Y = C + T, K = G + T, H = A + T + C, B = G + T + C, D = G + A + T, V = A + C + G, N = A + C + G + T). Whether two types of nucleic acids are homologous can be determined by direct sequence comparison or by hybridization under stringent conditions. When two nucleic acid sequences are compared directly, the genes are homologous if there is typically at least 50% identity between the nucleic acid sequences, preferably at least 70% identity, and more preferably at least 80%, 90%, 95%, 96%, 97%, 98% or 99% identity between the nucleic acid sequences.
[0067] Amino acids may be referred to herein by either their commonly known three-letter symbols or the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides may also be referred to by their commonly accepted one-letter codes. Herein, comparisons of amino acid and base sequence similarity, identity, and homology are calculated using the sequence analysis tool BLAST with default parameters. Identity searches can be performed, for example, using NCBI's BLAST 2.10.1+ (published June 18, 2020). Identity values herein generally refer to values obtained when aligned using the above-mentioned BLAST under default conditions. However, if parameter changes result in higher values, the highest value is used as the identity value. When identity is evaluated in multiple regions, the highest value among them is used as the identity value. Similarity is a numerical value that takes into account not only identity but also similar amino acids.
[0068] Unless otherwise specified, reference herein to a biological substance (e.g., a protein, nucleic acid, or gene) is understood to also refer to variants of that biological substance (e.g., variants with modifications in the amino acid sequence) that perform biological functions similar to, but not necessarily to, the biological function of the biological substance. Such variants may include fragments of the original molecule, molecules that are at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% identical across the amino acid or nucleic acid sequence of the original biological substance of the same size, or molecules that are at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, or 99% identical to the sequence of the original molecule when compared to the sequence of the original molecule as aligned by computer homology programs known in the art. Variants may include molecules with modified amino acids (e.g., modifications due to disulfide bond formation, glycosylation, lipidation, acetylation, or phosphorylation) or modified nucleotides (e.g., modifications due to methylation).
[0069] As used herein, the term "stringent conditions" refers to well-known conditions commonly used in the art. Examples of stringent conditions include the following: (1) using low ionic strength and high temperature for washing (e.g., 0.015 M sodium chloride / 0.0015 M sodium citrate / 0.1% sodium dodecyl sulfate at 50°C), (2) using a denaturing agent such as formamide during hybridization (e.g., 50% (v / v) formamide and 0.1% bovine serum albumin / 0.1% Ficoll / 0.1% polyvinylpyrrolidone / 50 mM pH 7.0 at 42°C). (3) Incubate overnight at 37°C in a solution containing 20% formamide, 5x SSC, 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 mg / ml denatured, sheared salmon sperm DNA. The filter is then washed with 1x SSC at approximately 37-50°C. The formamide concentration may be 50% or higher. Washing times may be 5, 15, 30, 60, or 120 minutes or longer. Several factors, including temperature and salt concentration, can affect the stringency of the hybridization reaction. For details, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995). Examples of "highly stringent conditions" are 0.0015 M sodium chloride, 0.0015 M sodium citrate at 65-68°C, or 0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide at 42°C.Hybridization can be performed in accordance with the methods described in experimental manuals such as Molecular Cloning 2nd ed., Current Protocols in Molecular Biology, Supplement 1-38, and DNA Cloning 1: Core Techniques, A Practical Approach, Second Edition, Oxford University Press (1995). Sequences that hybridize under stringent conditions preferably exclude sequences containing only A sequences or only T sequences. Moderately stringent conditions can be easily determined by those skilled in the art, for example, based on the length of the DNA, and are described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Vol. 3, Vol. 1, pp. 7.42-7.45, Cold Spring Harbor Laboratory Press, 2001, and includes the use of hybridization conditions for nitrocellulose filters, with a pre-wash solution of 5xSSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), about 50% formamide, 2xSSC-6xSSC (or other similar hybridization solutions, such as Stark's solution in about 50% formamide at about 42°C), at about 40-50°C, and wash conditions of 0.5xSSC, 0.1% SDS at about 60°C. Thus, the term "polypeptide" as used in the present disclosure also encompasses polypeptides encoded by nucleic acid molecules that hybridize under high or moderate stringency conditions to nucleic acid molecules encoding the polypeptides specifically described in the present disclosure.
[0070] As used herein, a "corresponding" amino acid or nucleic acid refers to an amino acid or nucleotide in a polypeptide or polynucleotide molecule that has or is predicted to have the same function as a given amino acid or nucleotide in a reference polypeptide or polynucleotide. In particular, in the case of an enzyme molecule, this refers to an amino acid that is located at a similar position in the active site and contributes similarly to catalytic activity. For example, in the case of an antisense molecule, this may be a similar portion in an orthologue corresponding to a specific portion of the antisense molecule. A corresponding amino acid may be, for example, a specific amino acid that is cysteinylated, glutathionylated, forms an S-S bond, oxidized (e.g., methionine side chain oxidation), formylated, acetylated, phosphorylated, glycosylated, myristylated, or the like. Alternatively, the corresponding amino acid may be an amino acid responsible for dimerization. Such a "corresponding" amino acid or nucleic acid may be a region or domain spanning a certain range. Therefore, in such cases, it is referred to herein as a "corresponding" region or domain.
[0071] As used herein, a "corresponding" gene (e.g., a polynucleotide sequence or molecule) refers to a gene (e.g., a polynucleotide sequence or molecule) that has or is predicted to have the same function in a certain species as a given gene in a species used as a reference for comparison. When multiple genes with such function exist, the term refers to genes that have the same evolutionary origin. Thus, a gene corresponding to a certain gene may be an ortholog of that gene. For example, the cap of serotype 1 AAV may correspond to the cap of serotype 2 AAV. For example, a corresponding gene in a certain virus can be found by searching a sequence database for that virus using the gene sequence of the reference virus for the corresponding gene as a query sequence.
[0072] In accordance with the present disclosure, the term "activity" as used herein refers to the function of a molecule in the broadest sense. Activity generally includes, but is not limited to, the biological, biochemical, physical, or chemical function of a molecule. Activity includes, for example, enzymatic activity, the ability to interact with other molecules, and the ability to activate, promote, stabilize, inhibit, suppress, or destabilize the function of other molecules, stability, and the ability to localize to a specific subcellular location. Where applicable, the term also relates to the function of a protein complex in the broadest sense.
[0073] As used herein, the term "biological function," when referring to a gene or a nucleic acid molecule or polypeptide related thereto, refers to a specific function that the gene, nucleic acid molecule, or polypeptide may have in a living organism. Examples of such functions include, but are not limited to, the ability to recognize a specific cell surface structure, enzymatic activity, and the ability to bind to a specific protein. In the present disclosure, examples of such functions include, but are not limited to, the ability of a promoter to be recognized in a specific host cell. As used herein, biological function can be exerted through "biological activity." As used herein, "biological activity" refers to the activity that a certain factor (e.g., a polynucleotide, a protein, etc.) may have in a living organism, and includes various functions (e.g., transcription-promoting activity), including, for example, the activation or inactivation of another molecule through interaction with another molecule. For example, if a certain factor is an enzyme, its biological activity includes its enzymatic activity. In another example, if a certain factor is a ligand, its biological activity includes the binding of the ligand to its corresponding receptor. Such biological activity can be measured using techniques well known in the art. Thus, "activity" refers to various measurable indicators that demonstrate or reveal binding (either directly or indirectly); affect a response (i.e., have a measurable effect in response to some exposure or stimulus), including, for example, a measure of the amount of an upstream or downstream protein or other similar function in a host cell.
[0074] As used in this disclosure, the "infectivity" of a virus or viral vector refers to the ability of the virus or viral vector to introduce nucleic acid within the virus or viral vector into a cell by attachment to or membrane fusion with the cell. Sendai virus vectors may have the same replication ability as wild-type vectors, or may be weakened by genetic mutation. The "replication ability" of a virus or viral vector refers to the ability to produce infectious viral particles or viral vector particles within infected cells.
[0075] As used herein, the terms "transformation," "transduction," and "transfection" are used interchangeably unless otherwise specified, and refer to the introduction of nucleic acid into a host cell (optionally via a virus or viral vector). Any method for introducing nucleic acid into a host cell can be used as the transformation method, and various well-known techniques, such as the use of competent cells, electroporation, particle gun (gene gun) methods, and calcium phosphate methods, can be used.
[0076] As used herein, a "purified" substance or biological factor (e.g., a nucleic acid or protein) refers to a biological factor from which at least a portion of the factors naturally associated with the biological factor have been removed. Thus, the purity of the biological factor in a purified biological factor is typically higher (i.e., more concentrated) than in the state in which the biological factor normally exists. As used herein, the term "purified" preferably means that at least 75% by weight, more preferably at least 85% by weight, even more preferably at least 95% by weight, and most preferably at least 98% by weight of the same type of biological factor is present. The substance used in the present disclosure is preferably a "purified" substance.
[0077] As used herein, the terms "drug," "agent," or "factor" (all of which correspond to the English term "agent") are used interchangeably in a broad sense and may refer to any substance or other element (e.g., energy such as light, radioactivity, heat, or electricity) that can achieve the intended purpose. Examples of such substances include, but are not limited to, proteins, polypeptides, oligopeptides, peptides, polynucleotides, oligonucleotides, nucleotides, nucleic acids (e.g., DNA such as cDNA and genomic DNA, and RNA such as mRNA), polysaccharides, oligosaccharides, lipids, small organic molecules (e.g., hormones, ligands, signaling substances, small organic molecules, molecules synthesized by combinatorial chemistry, small molecules that can be used as pharmaceuticals (e.g., small molecule ligands), etc.), composite molecules thereof, and mixtures thereof.
[0078] As used herein, the terms "complex" or "complex molecule" refer to any construct comprising two or more moieties. For example, if one moiety is a polypeptide, the other moiety may be a polypeptide or another substance (e.g., a substrate, a sugar, a lipid, a nucleic acid, another carbohydrate, etc.). As used herein, the two or more moieties constituting a complex may be bonded by a covalent bond or by other bonds (e.g., hydrogen bonds, ionic bonds, hydrophobic interactions, van der Waals forces, etc.).
[0079] The term "about" refers to the indicated value plus or minus 10%. When "about" is used in reference to temperature, it refers to the indicated temperature plus or minus 5° C., and when "about" is used in reference to pH, it refers to the indicated pH plus or minus 0.5.
[0080] (Preferred Embodiments) Preferred embodiments of the present disclosure will be described below. The embodiments provided below are provided for a better understanding of the present disclosure, and it is understood that the scope of the present disclosure should not be limited to the following description. Therefore, it is clear that those skilled in the art can make appropriate modifications within the scope of the present disclosure in light of the description in this specification. It is also understood that the following embodiments can be used alone or in combination.
[0081] In one aspect, the present disclosure provides a method for producing a strain having a desired property, the method comprising the steps of: 1) providing a construct comprising a gene cluster containing multiple genes, wherein the construct has multiple promoters introduced therein; 2) creating a combinatorial library of the promoters in the construct; and 3) selecting a strain having the desired property in a host cell. In this aspect, the multiple promoters may be arranged monocistronically.
[0082] In another aspect, the present disclosure provides a method for producing a substance in a host organism, the method comprising: (A) constructing a construct in which a promoter introduction site and a sequence for reconstruction are added to a group of genes involved in the production of the substance from which undesired restriction enzyme recognition sequences have been eliminated; (B) introducing multiple types of constructs, each having a promoter introduced into the promoter introduction site, into a host organism for creating a combinatorial library; (C) constructing a host organism for creating a combinatorial library from the construct; TM (D) culturing a host organism for production having the constructs in the combinatorial library and selecting a plurality of strains based on an arbitrary criterion; (E) substituting the promoter sites in the constructs of the plurality of strains into a combinatorial library using the Combi-OGAB method; TM (F) producing a substance using a strain having desired properties.
[0083] The arbitrary standard may be, for example, the top strains (e.g., the top five) with the highest substance production among multiple strains, or a predetermined production amount, and can be determined appropriately by a person skilled in the art.
[0084] In one aspect, a method for producing a strain having desired properties is provided, the method comprising the steps of: 1) providing a plurality of constructs each containing a gene cluster containing a plurality of genes, wherein the promoters are arranged in a monocistronic manner; 2) compiling a combinatorial library of the promoters in the constructs and introducing the library into a host cell of interest; and 3) selecting a strain having the desired properties in the host cell.
[0085] In another aspect, the present disclosure provides a method for producing a substance in a host organism, the method comprising: (A) constructing a construct in which a promoter introduction site and a sequence for reconstitution are added to a group of genes involved in the production of the substance from which undesired restriction enzyme recognition sequences have been eliminated; (B) introducing into the host organism a plurality of constructs in which a promoter has been introduced into the promoter introduction site; (C) expressing Combi-OGAB in a cell of the host organism; TM (D) culturing the host organism and selecting multiple strains having desired properties; (E) combining the promoter sites in the constructs of the multiple strains having the desired properties into a combinatorial library using the Combi-OGAB method. TM (F) producing a substance using a strain having desired properties.
[0086] In another aspect, the present disclosure provides a method of producing a substance in a host organism, the method comprising producing the substance with a strain produced according to the methods of the present disclosure.
[0087] In another aspect, the present disclosure provides a method for producing a substance in a host organism, the method comprising the step of producing the substance with a strain obtained by steps (A) to (E) of the method of the present disclosure.
[0088] The methods of the present disclosure may further include modifying the strains of the present disclosure. Modifications may include mutations, adding other genes such as transporters and / or other metabolic enzymes, etc. Such modifications may optimize the properties of the strain.
[0089] In one embodiment, examples of strains having desired properties include strains that can produce a target substance, strains that highly produce a target substance, strains that retain the target substance within the bacterial cell and do not secrete it, strains that secrete the target substance outside the bacterial cell, target substance-producing strains that are easy to culture (for example, grow under common culture conditions (medium, temperature, culture time, etc.)), strains that can produce multiple target substances in desired ratios, strains that produce a target substance without producing harmful substances (non-toxic, etc.), strains that produce a robust amount of a target substance, strains that do not develop defects in genes that produce a target substance during the culture period, strains that can control the production of a target substance, strains that can suppress the production of substances other than the target, strains that can suppress the production of by-products and / or impurities that are difficult to separate by affinity, ion exchange, gel filtration, reverse phase, normal phase, chiral chromatography, distillation, crystallization, etc., strains that produce a low amount of empty capsids in viral vector production, strains that do not develop defects in plasmids, and any combinations thereof, but are not limited to these.
[0090] In one embodiment, the strain having the desired properties is a strain that at least produces a target substance at a high level, and may further have one or more of the desired properties described above, if necessary.
[0091] (Construct Preparation) A nucleic acid containing a nucleic acid sequence for producing a viral vector, which has a sequence for replication in bacteria, can be introduced into a host cell to form a plasmid in the host cell. TMIn one embodiment, the nucleic acid to be introduced in this method does not have to be a plasmid, since strains such as Bacillus subtilis may have the ability to form a plasmid from an exogenously introduced nucleic acid. For example, when Bacillus subtilis comes into contact with a nucleic acid (e.g., a non-circular nucleic acid having a tandemly repeated nucleic acid sequence), the nucleic acid can be taken up and form a plasmid within Bacillus subtilis (e.g., OGAB as described herein). TM (See the method described in WO 2022 / 097646 for details on construct production.)
[0092] (Combinatorial library construction) Combinatorial library construction will be explained. The following is an example, and other methods may also be used. A construct is constructed to which a promoter insertion site and a sequence for reconstruction are added. As described above, OGAB was used to construct the plasmid. TMThe method can be preferably used. The sequences for reconstruction can be SfiI, AarI, AlwNI, BbsI, BbvI, BcoDI, BfuAI, BglI, BsaI, BsaXI, BslI, BsmAI, BsmBI, BsmFI, BspMI, BspQI, BstAPI, BstXI, BtgZI, DraIII, EarI, Esp3I, FokI, HgaI, MwoI, PflMI, SfaNI, or SapI recognition sequences, and similar sequences can also be used, with N residues generated upon cleavage. Various promoters are introduced upstream of each gene in the gene cluster to construct a seed plasmid for combinatorial library creation. Multiple promoters with different transcription initiation times and / or transcription strengths are selected. After creating a combinatorial library, host cells can be transduced with each construct in the library, and one or more strains with desired properties can be selected. The selected strains can then be used for further combinatorial library creation. Repeating the cycle of combinatorial library creation, transduction, and strain selection multiple times can yield strains with better properties and / or multiple properties (fine tuning). For example, fine tuning the enzymes described in D.B. Basnet, et al., J. Biotechnol., 2008, 135, 92-96 (EryCIII enzyme reaction, EryK / EryG enzyme reaction); Appl. Microbiol. Biotechnol., 2017, 101, 5951 can improve the production yield (content in a fraction) of the desired substance. The cycle can be performed two or more times, for example, two, three, four, or five times.
[0093] The selection of strains to be used in the second cycle of combinatorial library creation may be performed based on any criteria. For example, the top five strains in terms of desired properties (e.g., high production of a target substance) may be selected, or strains that satisfy a predetermined property (e.g., production of a target substance exceeding that of a natural strain) may be selected. The strains selected for the second cycle may be 2 or more, 50 or more, 100 or more, 1,000 or more, or 10,000 or more. Preferably, 2 or more strains are selected for the second cycle. The number of strains used in the second cycle is the maximum number of transformants that can be obtained, and may be, for example, 10, 15, 20, 30, 40, 50, or 100. The minimum and maximum number of strains selected may be any number between the above values.
[0094] (Preparation of Assembly Nucleic Acid) The procedure for preparing an assembly nucleic acid to be incorporated into a transformed organism will be described below.
[0095] Preparation of Nucleic Acid Units Nucleic acid unit molecules to be incorporated into the nucleic acid assembly are prepared. Nucleic acid unit molecules can be produced by any known method, such as polymerase chain reaction (PCR) or chemical synthesis. The nucleic acid unit molecules can have any desired sequence, such as a sequence or part thereof encoding a desired protein (e.g., metabolic enzyme, natural product biosynthetic enzyme group, artificial enzyme, therapeutic protein, protein constituting a viral vector), a sequence controlling a gene (e.g., promoter, enhancer), or a sequence for manipulating nucleic acids (e.g., restriction enzyme recognition sequence). The ends of each nucleic acid unit molecule can be configured to produce specific overhanging sequences so that multiple types of nucleic acid unit molecules are arranged in a specific order and / or specific orientation when incorporated into the nucleic acid assembly.
[0096] Since a large number of nucleic acid unit molecules can ultimately be assembled on a plasmid, one or more nucleic acid unit molecules may be designed to encode one or more long genes, such as a group of genes constituting a series of metabolic pathways or a protein complex composed of multiple subunits.
[0097] - Preparation of unit vectors Unit vectors can be prepared by linking unit nucleic acids with additional nucleic acids that are different from the unit nucleic acids. Use of unit vectors may make it easier to handle unit nucleic acids.
[0098] The additional nucleic acid may be a linear nucleic acid or a circular plasmid. When a circular plasmid is used as the additional nucleic acid, the unit vector may also have a circular structure, and therefore may be used, for example, for transformation of E. coli or the like. In one embodiment, the additional nucleic acid may contain an origin of replication so that the unit vector is replicated in the host into which it is introduced. In one embodiment, all of the unit nucleic acids for constructing a certain nucleic acid assembly may be linked to the same type of additional nucleic acid, thereby reducing the size difference between the unit vectors and facilitating the handling of multiple types of unit vectors. In one embodiment, the unit nucleic acids for constructing a certain nucleic acid assembly may be linked to different types of additional nucleic acids. In one embodiment, for one or more unit nucleic acids for constructing a certain nucleic acid assembly, the ratio or average of (base length of unit nucleic acid) / (base length of unit vector) may be 50% or less, 40% or less, 30% or less, 20% or less, 15% or less, 10% or less, 7% or less, 5% or less, 2% or less, 1.5% or less, 1% or less, or 0.5% or less. The larger the size of the additional nucleic acid is than the unit nucleic acid, the more uniform the handling of different types of unit vectors may be. The unit nucleic acid and the additional nucleic acid can be linked by any method, for example, ligation using DNA ligase, TA cloning, etc. In one embodiment, for one or more unit nucleic acids used to construct a certain assembled nucleic acid, the ratio or average of (base length of unit nucleic acid) / (base length of unit vector) may be 1% or more, 0.3% or more, 0.1% or more, 0.03% or more, 0.01% or more, 0.003% or more, or 0.001% or more, which may facilitate the manipulation of the unit vector.
[0099] In one embodiment, the length of the unit nucleic acid may be 10 bp or more, 20 bp or more, 50 bp or more, 70 bp or more, 100 bp or more, 200 bp or more, 500 bp or more, 700 bp or more, 1000 bp or more, or 1500 bp or more, and 5000 bp or less, 5000 bp or less, 2000 bp or less, 1500 bp or less, 1200 bp or less, 1000 bp or less, 700 bp or less, or 500 bp or less.
[0100] In one embodiment, the nucleic acid assembly can be constructed from 2 or more, 4 or more, 6 or more, 8 or more, 10 or more, 15 or more, 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, or 100 or more types of nucleic acid units, and 1,000 or less, 700 or less, 500 or less, 200 or less, 120 or less, 100 or less, 80 or less, 70 or less, 60 or less, or 50 or less types of nucleic acid units. By adjusting the molar numbers of each nucleic acid unit (or vector unit) to be approximately the same, a desired nucleic acid assembly having a tandem repeat structure can be efficiently produced.
[0101] In one embodiment, the nucleic acid unit may have a base length that divides one set of repeat sequences in the nucleic acid assembly approximately equally by the number of nucleic acid unit sequences. This can facilitate the operation of adjusting the molar number of each nucleic acid unit (or unit vector). In one embodiment, the nucleic acid unit may have a base length that is increased or decreased by 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 7% or less, or 5% or less from the base length that divides one set of repeat sequences in the nucleic acid assembly approximately equally by the number of nucleic acid unit sequences.
[0102] In one embodiment, the nucleic acid unit molecules can be designed to have non-palindromic sequences (sequences that are not palindromic sequences) at the ends of the nucleic acid unit molecules. When the non-palindromic sequences of the nucleic acid unit molecules designed in this way are made into protruding sequences, they can easily give rise to a structure in which the nucleic acid unit molecules are linked to each other while maintaining their order in the assembled nucleic acid.
[0103] - Preparation of Assembly Nucleic Acids Assembly nucleic acids can be constructed by linking unit nucleic acids to each other. In one embodiment, unit nucleic acids can be prepared by excising them from unit vectors using a restriction enzyme or the like. Assembly nucleic acids can contain one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more sets of repeat sequences. The repeat sequences in the assembly nucleic acid can include the sequences of the unit nucleic acids and, if necessary, the sequences of the assembly vector nucleic acids. Assembly nucleic acids can have a sequence that enables replication of the nucleic acid in a transformed organism. In one embodiment, the sequence that enables replication of the nucleic acid in a transformed organism can include an origin of replication that is effective in the transformed organism (e.g., Bacillus bacteria (Bacillus subtilis)). The sequence of a replication origin effective in Bacillus subtilis is not particularly limited, and examples of those having a θ-type replication mechanism include sequences of replication origins contained in plasmids such as pTB19 (Imanaka, T., et al. J. Gen. Microbioi. 130, 1399-1408.(1984)), pLS32 (Tanaka, T and Ogra, M. FEBS Lett. 422, 243-246.(1998)), and pAMβ1 (Swinfield, TJ, et al. Gene 87, 79-90.(1990)).
[0104] The nucleic acid integrant may contain additional base sequences as needed in addition to the nucleic acid units. In one embodiment, the nucleic acid integrant may contain base sequences that control transcription / translation, such as a promoter, operator, activator, or terminator. Specific examples of promoters when Bacillus subtilis is used as a host include Pspac (Yansura, D. and Henner, DJ Pro. Natl. Acad. Sci. USA 81, 439-443 (1984)), whose expression can be controlled by IPTG (isopropyl sD-thiogalactopyranoside), and Pr promoter (Itaya, M. Biosci. Biotechnol. Biochem. 63, 602-604 (1999)).
[0105] The nucleic acid unit molecules can form a repeat structure in the assembled nucleic acid, maintaining a specific order and orientation. In one embodiment, by constructing the nucleic acid unit molecules such that the base sequences of the protruding ends of the nucleic acid unit molecules excised from the unit vectors are complementary to each other, it may be possible to form a repeat structure in the assembled nucleic acid, maintaining a specific order and orientation. In one embodiment, by making the structure of the protruding end unique for each different nucleic acid unit molecule, it is possible to efficiently form a repeat structure in a specific order and orientation. In one embodiment, the protruding end may have a non-batch sequence and may be either a 5'-end protruding or a 3'-end protruding.
[0106] In one embodiment, a nucleic acid unit having a cohesive end can be excised from a unit vector using a restriction enzyme. In this embodiment, the unit vector may have one or more restriction enzyme recognition sequences. When a unit vector has multiple restriction enzyme recognition sequences, the respective restriction enzyme recognition sequences may be recognized by the same restriction enzyme or by different restriction enzymes. In one embodiment, the unit vector may contain a pair of regions recognized by the same restriction enzyme, such that the complete nucleic acid unit region is contained between these regions. In an embodiment in which a restriction enzyme is used to cleave a recognition region, the unit vector may contain a region recognized by that restriction enzyme at the end of the nucleic acid unit region.
[0107] In one embodiment, when the same type of restriction enzyme is used to excise the nucleic acid units from multiple unit vectors, restriction enzyme treatment can be performed in a solution containing these multiple unit vectors, thereby improving work efficiency. The types of restriction enzymes used to prepare a certain nucleic acid assembly can be, for example, five or fewer, four or fewer, three or fewer, two or fewer, or one type, and using a small number of restriction enzymes can reduce variation in the number of moles between the nucleic acid units. In one embodiment, the nucleic acid units excised from the unit vectors can be easily purified by any known fractionation method, such as agarose gel electrophoresis.
[0108] The nucleic acid units and, if necessary, the integrated vector nucleic acid can be ligated to each other using DNA ligase or the like. This allows the production of an integrated nucleic acid. For example, the ligation of the nucleic acid units and, if necessary, the integrated vector nucleic acid can be carried out in the presence of components such as polyethylene glycol (e.g., PEG2000, PEG4000, PEG6000, PEG8000, etc.) and salt (e.g., monovalent alkali metal, sodium chloride, etc.). The concentration of each nucleic acid unit in the ligation reaction solution is not particularly limited and may be 1 fmol / μl or more. The reaction temperature and time for the ligation are not particularly limited and may be 37°C or more for 30 minutes or more. In one embodiment, before ligating the nucleic acid units and, if necessary, the integrated vector nucleic acid, a composition containing the nucleic acid units and, if necessary, the integrated vector nucleic acid may be subjected to any conditions that inactivate the restriction enzyme (e.g., phenol-chloroform treatment).
[0109] The nucleic acid unit molecules can be adjusted to approximately the same number of moles using, for example, the method described in WO 2015 / 111248. By adjusting the nucleic acid unit molecules to approximately the same number of moles, a desired assembled nucleic acid having a tandem repeat structure can be efficiently produced. The number of moles of the nucleic acid unit molecules can be adjusted by measuring the concentration of the unit vector or nucleic acid unit.
[0110] - Preparation of Plasmid from Accumulated Nucleic Acid Plasmids can be formed in transformed organisms by contacting the accumulated nucleic acid with the transformed organism. In one embodiment, transformed organisms include bacteria of the genus Bacillus, S. streptococcus, Haemophilus, and Neisseria. Examples of Bacillus bacteria include B. subtilis, B. megaterium, and B. stearothermophilus, but any transformed organism capable of forming a plasmid from the accumulated nucleic acid can be used. In one embodiment, the transformed organism into which the accumulated nucleic acid is introduced is competent and can actively take up nucleic acid. For example, competent Bacillus subtilis cleaves the double-stranded nucleic acid substrate on the cell, degrades one of the two strands from the cleavage site, and incorporates the other single strand into the cell. The incorporated single strand can be repaired to a circular double-stranded nucleic acid within the cell. Any known method can be used to make a transformed organism competent. For example, Bacillus subtilis can be made competent using the method described in Anagnostopoulou, C. and Spizizen, J.B. Acteriol., 81, 741-46 (1961). A known transformation method suitable for each transformed organism can be used.
[0111] In one embodiment, the present disclosure provides a vector plasmid produced from packaging cells. In one embodiment, the vector plasmid produced from packaging cells can be purified using any known method, and the present disclosure also provides a vector plasmid purified in this manner. In one embodiment, the presence of the desired nucleic acid sequence in the purified vector plasmid can be confirmed by examining the size pattern of fragments generated by restriction enzyme cleavage, PCR, nucleotide sequencing, or the like. In one embodiment, a vector plasmid-containing composition prepared by the vector plasmid production method of the present disclosure may contain a small amount of endotoxin. In one embodiment, a Bacillus subtilis containing the vector plasmid of the present disclosure is provided.
[0112] In the present disclosure, the transformed organism (host cell) used may be selected from Bacillus subtilis, actinomycetes, filamentous fungi, yeast, hydrogen bacteria, coryne bacteria, or animal cells. A preferred transformed organism is Bacillus subtilis. These transformed organisms are preferably capable of producing plasmids from the accumulated nucleic acids. The transformed organisms used to generate plasmids from the accumulated nucleic acids and create a combinatorial library may be the same or different from the transformed organisms used to produce the substance. For example, Bacillus subtilis may be used as the transformed organism for creating a combinatorial library, and the same Bacillus subtilis may be used as the transformed organism for producing the substance, or another transformed organism, such as actinomycetes, filamentous fungi, yeast, hydrogen bacteria, coryne bacteria, or animal cells, may be used.
[0113] In one embodiment, the unwanted restriction enzyme recognition sequence is OGAB TM Law, Combi-OGAB TM The restriction enzyme recognition sequence may be a restriction enzyme recognition sequence used in the method, for example, a Type IIS restriction enzyme recognition sequence selected from the group consisting of AarI, BsaI, BbsI, BsmBI, and BspQI, or a sequence for reconstruction such as an SfiI recognition sequence.
[0114] In one embodiment, the gene cluster associated with substance production may be a gene cluster for biosynthetic enzymes of polyketide synthase (PKS), non-ribosomal peptide synthase (NRPS), ribosomal translation system post-translationally modified peptides (RiPPs), or terpene biosynthetic enzymes.
[0115] Promoter combinations in constructing strains having desired properties in the present disclosure include PabrB, PvalS, Phag, PspoVG, PyvyD, Phema, Pffh, PsdhB, PiolS, PspoOA, PglyA, PyceC, PsrfAA, PyrxA, PytxG, PytvI, PspoVB, PphrK, PphrF, PftsH, Pasd, Pspo0F, PmenB, PgltX, Pmi nC, PphrC, PspoVS, PlicH, Pcdd, PflgM, PcheV, PcitZ, PclpQ, PphrG, PlytR, Phbs, PodhA, PsecA, PphrE, PftsZ, PxpaC, PcsbA, PywjC, PyknW, PysdB, PrapI, PyteJ, PureA, PtrxA, Pdps, PxynA, PrsbW, PspoIVCA, PyqfY, PyqeZ, PyabR, PkinA, PnadE, PsigH, PresE, PspsA, PgspA, PyflG, Pveg, Pgap, PahpC, PyvrE, PytkL, PyfkJ, PdegS, PpyrAB, PyacL, PywkA, Psp oVT, PywtG, PpdhC, PyuzA, PyhdF, PalsD, PpurE, PythP, PcomK, PptsI, PgtaB, PkatX, PydbP, PyqgZ, PydjO, PlytE, Pgsi Examples of promoters that can be used include any combination selected from the group consisting of Bacillus subtilis, PywrE, PopuE, PyoxA, PthrS, PbltD, PyfhL, PyraD, PydaD, PywnJ, PrelA, PydfK, PgerBC, PyitG, PybfO, PcotH, PylnF, PribT, PrapH, PmmgA, PyqfD, and PsigW, but are not limited to these, and other promoters that are growth phase-dependent of Bacillus subtilis can also be used as appropriate.
[0116] In this specification, "or" is used when "at least one or more" of the items listed in the sentence can be employed. The same applies to "alternative." In this specification, when it is specified that "within a range" of "two values," the range includes the two values themselves.
[0117] All references cited herein, including scientific literature, patents, patent applications, and the like, are incorporated by reference in their entirety to the same extent as if each were specifically set forth.
[0118] The present disclosure has been described above by showing preferred embodiments for ease of understanding. The present disclosure will be described below based on examples. However, the above description and the following examples are provided for illustrative purposes only and are not intended to limit the present disclosure. Therefore, the scope of the present disclosure is not limited to the embodiments or examples specifically described herein, but is limited only by the scope of the claims.
[0119] The present disclosure will be specifically described in the following examples, but the present disclosure is not limited to these examples. The reagents used were specifically products described in the examples, but equivalent products from other manufacturers (Sigma-Aldrich, Wako Pure Chemical Industries, Nakarai, R&D Systems, USCN LifeScience INC, etc.) can also be used.
[0120] <Reagents and Test Methods> The reagents and test methods used in the examples are as follows. The Marburg168 strain and the BUSY9797 strain, a derivative of the RM125 strain (Non-Patent Document 7), were used as Bacillus subtilis hosts. A modified version of pGETS151-pBR (Patent Document 2) (FIG. 1, SEQ ID NO: 1) was used as a plasmid vector replicable in Bacillus subtilis. The antibiotics carbenicillin, tetracycline, and kanamycin were manufactured by Nacalai Tesque. Lysozyme was purchased from Fujifilm Wako Pure Chemical Industries, Ltd. Restriction enzymes were manufactured by New England Biolab. T4 DNA Ligase was purchased from Takara Bio Inc. Takara Ligation Kit <Mighty Mix> (Takara Bio Inc.) was used for general ligation for constructing plasmids in E. coli. Toyobo's KOD Plus polymerase v. 2 was used for the PCR reaction to prepare the DNA fragments. Meanwhile, Takara Bio's Ex-Taq HS was used for colony PCR to determine the base sequence of DNA cloned into the plasmid. Plasmid Safe, an enzyme used to purify circular plasmids, was manufactured by EPICENTER. 2-Hydroxyethyl agarose, a low-melting-point agarose gel for DNA electrophoresis, was purchased from Sigma. Another common agarose used for electrophoresis was Invitrogen's UltraPure Agarose. TE-saturated phenol (containing 8-xylinol) was manufactured by Nacalai Tesque. LB medium components and agar were manufactured by Becton Dickinson. Reagents used for extraction from the cultured cells or culture medium and for HPLC analysis were manufactured by Nacalai Tesque.
[0121] The Escherichia coli JM109 strain was used for constructing the plasmid. A QIA prep Spin Miniprep Kit from Qiagen was used for small-scale purification of the constructed plasmid from E. coli. A Qiagen MinElute Reaction Cleanup Kit was used for purifying DNA from the enzyme reaction solution. A Thermo Nano Drop One ultra-microspectrophotometer was used. A 3500xL Genetic Analyzer, a fluorescent automated sequencer manufactured by Applied Biosystems, was used for determining the base sequence.
[0122] Other general DNA manipulations were performed according to standard protocols (Non-Patent Document 8). TM Transformation of Bacillus subtilis by the method and extraction of plasmids were performed as previously reported (Non-Patent Document 9).
[0123] 1. Construction of an Integration Plasmid Vector The integration plasmid vector pGETS151-pBR is an E. coli-B. subtilis shuttle plasmid vector containing the replication origin of E. coli pBR322 and the replication origin of B. subtilis pGETS151. A promoter was introduced into this vector to increase the plasmid copy number, and a point mutation was introduced into the BsmBI recognition sequence contained in pGETS151 to make it resistant to cleavage. This vector was used in this example. The structure is shown in Figure 1, and the base sequence is shown in SEQ ID NO: 1. This plasmid vector was cleaved with the restriction enzyme AarI and purified to obtain the pGETS151 vector, which has ATTA and AAAA overhangs and has no pBR322-derived sequences. These overhangs were used to introduce the target genes, thereby constructing a B. subtilis plasmid.
[0124] 2. Selection of Natural Product Biosynthetic Enzyme Gene Clusters The biosynthetic gene clusters (BGCs) featured in the examples of the present disclosure were Triketide Pyrone BGC (bpsA-bpsB), a type III PKS contained in the genome of Bacillus subtilis, and GramicidinS BGC (grsT-grsA-grsB), an NRPS contained in the genome of Aneurinibacillus migulanus DSM2895 strain. The production of the two substances featured here has not been detected in wild-type strains under normal conditions (Non-Patent Documents 10 and 11). In the examples shown below, Triketide Pyrone BGC was produced in Bacillus subtilis Marburg168, which contains the BGC in its genome (homologous production), and GramicidinS BGC was produced in Bacillus subtilis BUSY9797, which does not contain the BGC in its genome (heterologous production). In this study, the most important goal was to create strains capable of homologous or heterologous production of substances that are not produced or are produced only in trace amounts in wild-type hosts. To achieve this, we used a combinatorial library of growth-phase-dependent promoters with different transcription strengths for each gene constituting a gene cluster.
[0125] Example 1 (1) Preparation of seed plasmid for BGC-1 (Tricketide Pyrone BGC) In BGC-1, the Triketide Pyrone core is produced by the type III PKS BpsA, and the OH group on the core is further methylated by the methyltransferase BpsB. We attempted to obtain a strain that highly produces this methylated Triketide Pyrone (Pyrone-OMe) and a strain that reduces the residual unmethylated Triketide Pyrone (Pyrone-OH) produced by the intermediate BpsA. From the bpsA and bpsB sequences of Bacillus subtilis, sequences were designed that silenced the recognition sequences of BbsI and BsmBI, and 19 bp upstream of bpsA and 15 bp upstream of bpsB were added upstream of each gene, expecting that they would contain Shine-Dalgarno (SD) sequences on the wild-type genome. TMAn SfiI recognition sequence for Bacillus subtilis was introduced (SEQ ID NO: 2). This sequence was constructed using the MAP method (Patent Document 3) and then inserted into a vector for Bacillus subtilis (Figure 2). Cassettes with various promoters added downstream of the BBaK_780000 terminator were introduced into the construct (Table 1). The growth phase-dependent promoters described in Non-Patent Document 6 were used. The growth phase-dependent promoters used were: transcription initiated in the logarithmic growth phase (Class I), PabrB (transcription intensity: strong), PvalS (transcription intensity: medium), Phag (transcription intensity: weak), transcription initiated in mid-logarithmic growth to early stationary phase (Class II), PspoVG (transcription intensity: strong), PsrfAA (transcription intensity: medium), Pcdd (transcription intensity: weak), transcription initiated in the lag phase and stationary phase (Class III), PlytR (transcription intensity: strong), Pveg (transcription intensity: weak), transcription initiated in the stationary phase (Class IV), PmmgA (transcription intensity: strong), PyqfD (transcription intensity: medium), and PsigW (transcription intensity: weak). Plasmids in which these promoter cassettes were introduced into both bpsA and bpsB were first prepared and used as seed plasmids. Next, these 11 seed plasmids were used to create Combi-OGAB TM A combinatorial library was created by the method, and a search was conducted for promoter combinations with optimal transcription strength and transcription initiation time to derive strains that produce high amounts of Pyrone-OMe and strains that can suppress the residual Pyrone-OH.
[0126]
[0127] (2) Combi-OGAB TMScreening for high-methylated Triketide Pyrone-producing strains using the ELISA kit. Equal amounts of the 11 plasmids were mixed and cleaved with SfiI. The enzyme was inactivated with TE-saturated phenol, the aqueous phase was concentrated with 1-butanol, precipitated with ethanol, and the precipitate was dissolved in TE. This SfiI-treated fragment solution was religated with T4 DNA ligase, enriched in Marburg168 strain, plated on LB-10 μg / mL tetracycline-containing plates, and incubated overnight at 30°C. The resulting colonies were inoculated into 300 μL of LB-10 μg / mL tetracycline-containing liquid medium, cultured overnight at 30°C, and then frozen and stored at -70°C. To evaluate the amount of Triketide Pyrone biosynthesis in each strain, a frozen stock was inoculated into 10 mL of LB-10 μg / mL tetracycline-containing liquid medium and cultured at 37°C with shaking (1st cycle: 17 hours, 2nd-4th cycles: 24 hours). The culture was centrifuged at 8,000 g for 5 minutes, and the precipitate was collected. The precipitate was then suspended in 15 mL of purified water and centrifuged again. The precipitate was suspended in 5 mL of 150 mM NaCl and 20 mM HCl and incubated at 80°C for 30 minutes. 5 mL of ethyl acetate was added and the mixture was stirred for 30 seconds using a vortex mixer. The mixture was then centrifuged at 10,000 g for 10 minutes, and the organic layer was collected. The collected organic layer was evaporated to dryness and dissolved in 100 μL of methanol. This solution was centrifuged at 15,000 g for 5 minutes, and 20 μL of the supernatant was injected into HPLC to analyze the amount of Triketide Pyrone produced. The HPLC measurement conditions were as follows:
[0128] Column: COSMOSIL™ 5C18-MS-II Packed Column 4.6 mm ID x 150 mm Mobile phase A: 0.1% formic acid - purified water, Mobile phase B: methanol Gradient: (80% B, 3 min) - (80% → 98% B, 4 min) - (98% B, 18 min) Flow rate: 1 mL / min Detection: 280 nm
[0129] After the analysis was completed, multiple strains that produced high amounts of the target compound, Pyrone-OMe, were selected from the obtained data and cultured. Equal volumes of the overnight cultures were mixed, and the plasmid was extracted. Subsequently, SfiI treatment, ligation, transformation into Marburg168, and analysis were repeated until the production amount converged. Of the Triketide Pyrone derivatives that appeared in this study, the peak at m / z 350 was assigned to Pyrone-OMe, and the peak at m / z 336 was assigned to Pyrone-OH, and these were then quantified.
[0130] (3) Combi-OGAB TM Changes in the proportion of Pyrone-OMe high-producing strains per cycle In the first cycle, 144 strains were cultured individually, and 123 strains grew. These strains were extracted using the method described above and analyzed by HPLC. A library for the second cycle was constructed using 13 high-producing strains. All strains grew from the second cycle onward (Table 2). The production of the final product, Pyrone-OMe, reached its upper limit after three cycles (Figure 3). The promoter sequences of the top three high-producing strains of the target substance in the second and third cycles were analyzed, and three of the six strains had the PvalS-bpsA-PsrfAA-bpsB combination (Table 3). In other words, it was shown that the optimal combination of the PvalS (Class I-medium)-PsrfAA (Class II-medium) promoters is to create a Bacillus subtilis strain that highly produces Pyrone-OMe, and that Pyrone-OMe can be efficiently obtained by using this strain.
[0131]
[0132]
[0133] (4) Combi-OGAB TMChanges in the proportion of highly methylation-efficient strains per cycle. When Pyrone-OMe production was monitored for each cycle, some samples showed a high proportion of Pyrone-OMe relative to the total amount of Pyrone-OMe and the unmethylated form (Pyrone-OH) produced by BpsA that had not been methylated by BpsB. Therefore, the changes per cycle based on the production amounts were reanalyzed using the BpsB methylation rate (100 x Pyrone-OMe production / (Pyrone-OH production + Pyrone-OMe production)). This also increased with each cycle and converged after three cycles (Figure 4). The combination Pcdd-bpsA-PvalS-bpsB gave the highest methylation efficiency in the third cycle (Table 4). In other words, the Pcdd (Class II-weak)-PvalS (Class I-moderate) promoter combination was found to be optimal for producing a Bacillus subtilis strain that efficiently methylates Pyrone-OH. Although the amount of Pyrone-OMe produced with this promoter combination was not as high as with the PvalS-PsrfAA combination, it was demonstrated that it enabled efficient and simple separation of Pyrone-OH and Pyrone-OMe, which were detected at similar elution times on HPLC.
[0134]
[0135] Example 2
[0136] (1) Preparation of seed plasmid for BGC-2 (GramicidinS BGC) As with BGC-1, a promoter with appropriate transcription strength and transcription initiation time for the grsT, grsA, and grsB genes constituting GramicidinS BGC was searched for to identify the optimal promoter combination for high GramicidinS production. Sequences were designed that silenced the AarI, BsaI, BbsI, and BspQI recognition sequences from the grsT, grsA, and grsB sequences of the DSM2895 strain, and 20 bp upstream of grsT, 22 bp upstream of grsA, and 20 bp upstream of grsB of the DSM2895 strain were added upstream of each gene, with the expectation that they would contain SD sequences. Similarly to BGC-1, a promoter insertion site, Combi-OGAB, was also added. TMThis sequence was inserted into the 25-fragment OGAB TM Divided into blocks OGAB TM The vectors were synthesized by the method described above and integrated into a Bacillus subtilis vector (Figure 5). Similar to the BGC-1 promoter insertion site, a cassette containing one of the promoters PvalS (Class I medium), Phag (Class I weak), PspoVG (Class II strong), PsrfAA (Class II medium), Pcdd (Class II weak), PlytR (Class III strong), Pveg (Class III weak), PmmgA (Class IV strong), PyqfD (Class IV medium), or PsigW (Class IV weak) was inserted downstream of the BBaK_780000 terminator. This cassette was then inserted into all of grsT, grsA, and grsB to prepare a seed plasmid. Next, these 10 seed plasmids were used to create Combi-OGAB TM A combinatorial library was created by the method, and a search was conducted for a promoter combination with optimal transcription strength and transcription initiation time to derive a strain that produces high levels of Gramicidin S.
[0137] (2) Combi-OGAB TMScreening for Gramicidin S high-producing strains using the method. Equal amounts of the 10 plasmids were mixed and digested with SfiI. The enzyme was inactivated with TE-saturated phenol, the aqueous phase was concentrated with 1-butanol, and then ethanol precipitated. The resulting precipitate was dissolved in TE. The SfiI-treated fragment solution was religated with T4 DNA ligase and enriched in strain BUSY9797, which had been transformed with plasmid pUB8 (Non-Patent Document 12), encoding phosphopantethenylate transferase lpa-8. The resulting fragments were plated on LB-10 μg / mL tetracycline-kanamycin-containing plates and incubated overnight at 30°C. The resulting colonies were inoculated into 300 μL LB-10 μg / mL tetracycline-kanamycin-containing liquid medium, cultured overnight at 30°C, and then frozen and stored at -70°C. To evaluate Gramicidin S biosynthesis, a frozen stock was inoculated into 2 mL of YTG (Bacto Yeast Extract 50 g / L, BactoTryptone 50 g / L, glucose 5 g / L)-10 μg / mL tetracycline-kanamycin-containing liquid medium and cultured at 30°C for 72 hours with shaking. 2 mL of ethyl acetate was added to the culture, which was then stirred for 30 seconds using a vortex mixer. The culture was then centrifuged at 10,000 g for 10 minutes, and the organic layer was collected. The organic layer was evaporated to dryness and dissolved in 200 μL of 70% methanol-0.5% formic acid. This solution was centrifuged at 15,000 g for 5 minutes, and 20 μL of the supernatant was injected into an HPLC to analyze the amount of Gramicidin S produced. The HPLC measurement conditions were as follows: Column: COSMOSIL™ 5C18-AR-II Packed Column 4.6 mm ID x 150 mm Mobile phase A: 0.1% formic acid - pure water, Mobile phase B: methanol Gradient: (60% B, 5 minutes) - (60% → 78% B, 9 minutes) - (78% 100% B, 0.1 minutes) - (100% B, 5 minutes) Flow rate: 1 mL / min Detection: 210 nm After analysis, several high-producing strains were selected from the obtained data, and after re-cultivation, equal amounts of the cultures were mixed and plasmids were extracted. Thereafter, the library was reconstructed by SfiI treatment, and the production amount of each strain was measured in the same manner using Combi-OGAB. TMThe cycle was run until production converged.
[0138] (3) Changes in Gramicidin S Production Amounts Per Cycle In the first cycle, 192 strains were cultured individually, and 134 strains grew. Extraction from these strains using the method described above and analysis by HPLC revealed that some strains exhibited a unimodal peak on the chromatogram, while others exhibited a trimodal peak (Figure 6). Analysis of these peaks by LC-MS revealed that in the trimodal peak sample, m / z 1141, corresponding to the molecular weight of the target substance, Gramicidin S, as well as m / z 1155 and 1169, were detected. It has been reported that the L-Orn-selective domain of the Gramicidin S biosynthetic enzyme group also has L-Lys selectivity (Non-Patent Document 13), and that among wild-type producing strains, there are strains that produce Lys1- and 2-substitution products (Non-Patent Document 14). Since only promoter sequences were compiled into a library in this study, it was suggested that the promoter transcription initiation time or transcription strength was effective in suppressing the production of Lys-substituted Gramicidin S. To proceed to the second cycle, we attempted to re-culture strains that had highly produced Gramicidin S in the first cycle, but most strains were unable to be re-cultured. This process allowed us to easily eliminate constructs with poor reproducibility due to host compatibility. Plasmids were extracted from the seven strains that were successfully re-cultured and then transferred to the second cycle. Sixty strains were cultured in the second cycle, and 59 strains grew. Of these, 45 strains produced Gramicidin S, and only two strains showed a trimodal peak on the HPLC chromatogram. From the third cycle onwards, all strains grew, and no Gramicidin S non-producers or strains showing a trimodal peak on the HPLC chromatogram were observed (Table 5). After four cycles, it was confirmed that the Gramicidin S-producing strains converged after three cycles (Figure 7). When the promoter sequences of the top five Gramicidin S-producing strains after the third cycle were confirmed, all strains had the sequence PsigW-g rsT-Pcdd-grsA-PlytR-grsB.In other words, it was shown that the combination of PsigW (Class IV-weak)-Pcdd (Class II-weak)-PlytR (Class III-strong) is optimal for heterologous production of Gramicidin S in Bacillus subtilis.
[0139]
[0140] (4) Analysis of Gramicidin S Purity Using High-Producing Strains The biosynthetic extracts of the C2 strain (3rd-C2), the highest-producing strain in the third cycle, which showed a unimodal peak on the HPLC chromatogram, and the 1C11 strain (2nd-1C11), the strain in the second cycle, which showed a trimodal peak on the HPLC chromatogram, were analyzed by LC-MS and LC-MS / MS. The ratio of the target Gramicidin S:1Lys-substituted:2Lys-substituted strains in the 3rd-C2 strain was 95.56:3.58:0.86, whereas the ratio in the 2nd-1C11 strain was 75.63:14.62:9.75, confirming that the proportion of Lys-substituted by-products was high (Figure 8, Table 6). TM By optimizing the transcription initiation time and transcription strength of each promoter for each gene using this method, we were able to explore promoter combinations that not only increased production but also suppressed the production of Lys-substituted forms. The target Gramicidin S and Lys-substituted forms were detected at approximately the same elution time on HPLC. Therefore, improving purity in the purification process requires a great deal of time and cost, but by going through this process, we were able to find promoter combinations that could improve not only production volume but also the purity of the target product from the point of production.
[0141]
[0142] Many PKS and NRPS genes are present in the genomes of not only Bacillus subtilis but also actinomycetes and filamentous fungi. Therefore, it is expected that similar experimental results will be obtained for the PKSs and NRPSs of actinomycetes and filamentous fungi by conducting studies as in this example.
[0143] Example 3 This example demonstrates that promoter arrangement patterns (monocistronic, polycistronic), single or multiple gene cluster patterns, single or multiple construct patterns, and the like are possible.
[0144] For the Gramicidin S biosynthetic gene cluster described in Example 2, three types of transcriptional arrangements were designed: 1) a construct in which a promoter is placed only upstream of grsT, and the entire cluster is transcribed polycistronically; 2) a construct in which promoters are placed upstream of grsT and grsA, and grsT is transcribed monocistronically and grsA and grsB are transcribed polycistronically; and 3) a construct in which promoters are placed upstream of grsT and grsB, and grsT and grsA are transcribed polycistronically and grsB is transcribed monocistronically. Plasmids into which multiple types of Bacillus subtilis growth phase-dependent promoters have been introduced are prepared in the same manner as in Example 2.
[0145] In addition to the above three types, a plasmid containing a construct in which grsT, grsA, and grsB, as described in Example 2, are all monocistronically transcribed. Plasmid libraries of four types of transcription configurations are prepared individually or in combination to form a combinatorial library by the Combi-OGAB method. This makes it possible to screen not only the transcription initiation time and transcription strength of the promoter for each gene for high production of Gramicidin S, but also the transcription unit.
[0146] References Patent Document 1: KR102301301B1 Patent Document 2: Japanese Patent Application Publication No. 2021-184730 Patent Document 3: Japanese Patent Application Publication No. 2019-198236 Non-Patent Document 1: D. J. Newman, et. al., J. Nat. Prod., 83, 770 (2020) Non-Patent Document 2: C. C. Brett, et. al., Annu. Rev. Biochem., 90, 763 (2021) Non-Patent Document 3: Kang H-. S. et. al., ACS Synth. Biol. , 5(9),1002(2016) Reference non-patent document 4:Kim H. ,et. al. ,ACS Synth. Bio l. ,9(1),175(2020) Reference non-patent document 5:Amagai K. ,et. al. ,Sci. Rep. , 7,3382(2017) Reference non-patent document 6:Yang. S. ,et al. , Appl. Microbi ol. Biotechnol. , 101 (10), 4151-4161(2017) Reference non-patent document 7:Uozumi, T. ,et al. Molec. Gen. Genet. , 152, 65-69 (1977) Reference non-patent document 8: Sambrook, J. , et al. , Moleculear Clonining: A Laboratory Manufactured by Manufacture, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989) Reference non-patent document 9: Tsuge, K. , et al. , Nucleic Acid sRes. 31,e133(2003) Reference non-patented document 10: Grubbs, K. J. , et al. , mSystems. 2(6)(2017) Reference non-patented document 11: Berditsch M. , et al. , App. Env iron. Microbiol. , 73(20), 6620(2007) Reference non-patented document 12: Tsuge, K. , et al. , Arcch Microbiol. 165, 243-251(1996) Reference non-patented document 13: Stanisic. A. , et al. , Chem. ScI., 10, 10395-10399 (2019) References: Non-patented literature 14: Alenezi F., Front. Microbiol., 8, 517-527 (2017)
[0147] (Note) As described above, the present disclosure has been illustrated using preferred embodiments thereof, but it is understood that the scope of the present disclosure should be interpreted solely by the scope of the claims. It is understood that the patents, patent applications, and literature cited in this specification are incorporated by reference into this specification in their entirety as if the contents themselves were specifically set forth in this specification. This application claims priority to Japanese Patent Application No. 2023-95819 filed with the Japan Patent Office, the contents of which are incorporated by reference in their entirety into this application.
[0148] The present invention provides a method for producing a microbial strain that exhibits desired properties, such as high production and by-product suppression, by activating a desired gene cluster, such as genes constituting a gene cluster for natural product biosynthetic enzymes, and potentially novel substances that can be used in bioindustries such as pharmaceuticals, agriculture, fisheries, fragrances, food, textiles, chemicals, and the environment.
[0149] Sequence number 1: pGETS151 ΔBsmBI-pBR AAAAGGCCTTCTTGGCCGCCCTTCCGGTCGATATGAACAGCTTATTTACATAATTCACGTTATTGGTAGTTATAAATGA AATTCCTAATATCGGTTATGAAGTGAAATTGAATTTCTACTTGATCTTTTCTCCTATTTTTGTAAAATAAAATTAAAAATTAAGAAT ATTTAAATATTCAATGATTCATTTTTGCAGAAATCGGAGGAAGAATATATATGAAAAACATTTAACATTTCTCCAACAAGA TCCCCCCATATTGTTTAGATGAAATACTGAAATACTGAATTTAAAACTTAGTTTATATGTGTAAAATGTTTTAATCAAGTT TAGGAGGAATTAATTATGAAGTGTAATGAATAATGAATGAACGGTTCAATTAAAGGGGAAGCGTATCATTAACCC TATAAACTACGTCTGCCTATTATTGGAGGGTGAAATGTGAATACATCCTATTCACAATCGAATTTACACAACCAACCAA ATTTTAATTTGGCTTTGCATTTTATCTTTTTTAGCGTATTAAATGAAATGGTTTTGAACGTgTCATTACCTAGATATTGC AAATGATTTTAATAAACCACCAGCGAGTACAAACTGGGTGAACACAGCCTTATGTTAACCTTTTCCATTGGAACAGCTG TATATGGAAAGCTATCTGATCAATTAGGCATCAAAAGGTTACTCCTATTTGGAATTATAATAAATTGTTTCGGGTCGGTA ATTGGGTTTGTTGGCCATCTTTCTTTTCCTTACTTATTATGGCTCGTTTTATTCAAGGGGCTGGTGCAGCTGCATTTCC AGCACTCGTAATGGTTGTAGTTGCCGCTATATTCCAAAGGAAAAATAGGGGTAAAGCATTTGGTCTTATTGGATCGATAG TAGCCATGGGAGAAGGAGTCGGTCCAGCGGATTGGTGGAATGATAGCCCATTATATTCATTGGTCCTATCTTCTACTCATTCCTATGATAACAATTATCACTGTTCCGTTTCTTATGAAATTATTAAAGAAAGAAGTAAGGATAAAAGGTCATTTTGATAT CAAAGGAATTATACTAATGTCTGTAGGCATTGTATTTTTTATGTTGTTTACAACATCATATAGCATTTCTTTTCTTATCG TTAGCGTGCTGTCATTCCTGATATTTGTAAAACATATCAGGAAAGTAACAGATCCTTTTGTTGATCCCGGATTAGGGAAA AATATACCTTTTATGATTGGAGTTCTTTGTGGGGGAATTATATTTGGAACAGTAGCAGGGTTTGTCTCTATGGTTCCTTA TATGATGAAAGATGTTCACCAGCTAAGTACTGCCGAAATCGGAAGTGTAATTATTTTCCCTGGAACAATGAGTGTCATTA TTTTCGGCTACATTGGTGGGATACTTGTTGATAGAAGAGGTCCTTTATACGTGTTAAACATCGGAGTTACATTTCTTTCT GTTAGCTTTTTAACTGCTTCCTTTCTTTTAGAAACAACATCATGGTTCATGACAATTATAATCGTATTTGTTTTAGGTGG GCTTTCGTTCACCAAAACAGTTATATCAACAATTGTTTCAAGTAGCTTGAAACAGCAGGAAGCTGGTGCTGGAATGAGTT TGCTTAACTTTACCAGCTTTTTATCAGAGGGAACAGGTATTGCAATTGTAGGTGGTTTATTATCCATACCCTTACTTGAT CAAAGGTTGTTACCTATGGAAGTTGATCAGTCAACTTATCTGTATAGTAATTTGTTATTACTTTTTTCAGGAATCATTGT CATTAGTTGGCTGGTTACCTTGAATGTATATAAACATTCTCAAAGGGATTTCTAAATCGTTAAGGGATCAACTTTGGGAG AGAGTTCAAAATTGATCCTTTTTTTATAACAGGAATTGGGCATCAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAG CAACGGCCCGGAGGGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAAATTAAGCAGAAGGCCATCCTGACGGA TGGCCTTTTTGCGTTTCTACAAACTCTTCCTGTCGTCATATCTACAATTCTACACAGCCCAGTCCAGACTATTGAATTGT ATCACGTTTTTGATATCCTACCAATAaCaAATTGATTGGAGGAATGCAAAGTGAATAATGAACCAGTAAAACGTGGTAAG AAGAACAGATGGGAATTAAACCTACCTATAATGACTTATGTAGTAGCTGATGATTGGATTGATAAACTAGGACACGAAAC GTTTACTTTATGGTTGAGGTTCCATACTTGGGTAGATAGAGAAGATGAACTCCGAGATTATGATCGCATACCTAGAAGTT TTGAGAACATATATAAAAAGACACTAGGAATCTCAAAAAGTAAGTTTTATAGATTGATAAAACCTTTATGGGAATATGGA TTAATAGACATCATAGAATACGAAGAATCTAACCGTAATTCTACTAAACCTAAAAATATAATTGTTTATGAGTATCCTTT ACACGAAATAGAAAGAAAGTATAAACCACTAGAAAAATTAAGAGATTGGGATAAAGACTATAATTCCGTTTCTAAAGAAT TAGGTAAAACAGGTGGTAGACCAAGGAAAAAAGATAGTGAAGAAGAACCCGAAAAGAAACCCGAAGAAGTAACTAAAAAG AAACGTAAATATAAGTTAAAAAGAGTTATCCACAACGGTTTCAAAAATGAAACGGTGGAGGGTTTCAAAAATGAAACGGT GGAGGGTTTCAAAAATGAAACGGTGACCGTTTCAAAAATAAAACCCAATAATTATTCAAATATCTTTAATAACTTATCAAATATTTCTACTAATGTTTCAAATAATTTATTAATTGATGATGATGAGGAAATCGAAAATGAACCAACTGGTCGTACAATA AATAGGTCATTACTTTTTTCACAAGAAGATATTAAACAGGCCTATCAATTTATTAATAGATTTTCAGTTATACAGTTACG TGAAAACTTTAGCTTTGATAAACACTTTGAAGAACGGTTGGTATGTTATTTATGGAAAGCAGGGATTTCTACTTTTTACA CGCACGAAATCAGTAAAATGATAAAAAAAATAGCAGACTATGAAAAATCTAAAAAAGGTAGATTAAACCCAATACGTGAC CGAGCCTTATATATGGTAAATGGTCTTGTAATGAATAGAGCTTCTTCCCAAAGTGAACATGCTACTTATAAACTAAACCA ATATAAAAAACAGAAGGAACAGGAAAAACAACAACAGGAGCAACAAAGATCAAGAGTACCGTTCTATAATTGGTTGGAGG AAAGAGAAGAACAAACCGAAGGTCAACTACCCACCACTTAAGCGGCCGCAAGCTTGAAGAGCTCTTCTTTCAGAACGCTC GGTTGCCGCCGGGCGTTTTTTATGAGAtGTCTCGGCCTGTTTGGCCATTAacgtgcaggtggatccagatctaagcttct atagaagcttggtaccgacgtctcggcctgtttggcccgccgcatccataccgccagttgtttaccctcacaacgttcca gtaaccgggcatgttcatcatcagtaacccgtatcgtgagcatcctctctcgtttcatcggtatcattacccccatgaac agaaatcccccttacacggaggcatcagtgaccaaacaggaaaaaaccgcccttaacatggcccgctttatcagaagcca gacattaacgcttctggagaaactcaacgagctggacgcggatgaacaggcagacatctgtgaatcgcttcacgaccacgctgatgagctttaccgcagctgcctcgcgcgtttcggtgatgacggtgaaaacctctgacacatgcagctcccgaagacg gtcacagcttgtctgtaagcggatgccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcgggtgtcgggg cgcagccatgacccagtcacgtagcgatagcggagtgtatactggcttaactatgcggcatcagagcagattgtactgag agtgcaccatatgcggtgtgaaataccgcacagatgcgtaaggagaaaataccgcatcaggcactcttccgcttcctcgc tcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccaca gaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgct ggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacag gactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatac ctgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgt tcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagt ccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggt gctacagagttcttgaagtggtggcctaactacggctacactagaaggacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgca agcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaac gaaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaag ttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcag cgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatct ggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagccagccggaag ggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagta gttcgccagttaatagtttgcgcaacgttgttgccattgctgcaggcatcgtggtgtcacgctcgtcgtttggtatggct tcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcgg tcctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcagcactgcataattctcttactg tcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcggcgaccg agttgctcttgcccggcgtcaacacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgat cttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagg gcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgag cggatacatatttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctggat ccacctgcacgt SEQ ID NO: 2: Triketide Pyorne BGC ATCGATCGGCAGGTGATGTCAATAACACCTGCATCGGGAATATGCAAAGAGGTGATCGCATGGCGTTTATTTTATCCATT GGAACAAGTCTaCCTGCGTATAATGTAAACCAAGAGAAAGCGGCCGAGTTCGCCCGCTATATGTTTCAGCATTCTTTTAA GGATATTGACAGGCTGTTATCCTCCTTTAAAAACGGGCAAATCCATTCGAGACAGTTTGTTAAGCCGATTGAATGGTATA AAGAGGGGCACAGCTTTGAAGAAAAAAATCAAATATACATAGAAGAAACACTTAAACACAGCAGAGCGGCTGTTCGTGAG TGCCTCTCTCATCCGGAATTTTTTCAAGAAGCCATTCCTTATGAGAAAGTGGAAGCTGTTTTTTTCGTgTCCAGTACAGG TCTTTCCACACCGAGTATCGAGGCGCGGCTTATGAATGAACTTCCGTTTTCTCCATATACGAAGCGGATTCCGATTTGGG GGCTTGGCTGTGCAGGAGGAGCCAGCGGACTTGCGCGTGCAGCCGAATACTGCAAAGCGTATCCTGAGGCTTTTGTGCTTGTCATTTCTGCCGAGCTGTGCAGCCTGACATTCCAGCCGGAAGATAAAACAAAAAGCAATCTGATCGGCACCTCGCTTTT TGGTGACGGCATTGCCGCAGCTTTATTATGCGGAGAGAAGGCGGACCGCAGGGTGTCAAAGCTGAAGCTTGCGCCGAAGA TAATGGACGCCCAATCTGTTTTGATGAAACAATCAGAAGATGTCATGGGCTGGGACTTTACCGATCAAGGATTCAAAGTC ATTTTCTCACGAGACATTCCGACCTTGGTGGAAAAATGGCTCAAAACAAATGTACAGATTTTTTTGGACAAACATAAGCT GTCATTCCATGATATCAGTGTTTTTTTGGCGCATCCAGGCGGAAAAAAAGTGATCGATGCATACATCAAAAGTCTCGGGC TGTCGTCAGAAAAGCTTTCATCTGCGCAAAGCATTTTGCAAAAGCACGGAAATATGTCaTCAGCCACAATCTTGTATGTG ATCAAAGACCATCTGCAGAACGGACATAAAAAGGAAGCTGAACGAGGACTGATTGGCGCATTAGGGCCGGGTTTCTCATC AGAGTTGCTATTATTCAGCTGGGAAAAGGGGGCCTGAGGCCTTGATGGCCATCGAGAGACCAATAATAATAGGTCTCAGG AAAAGGGGGCCTGACTCATGTTTTGGTTGTTGATCGCCATTCTCATTGTTCAAAGAGCAGCAGAAATGGCAGTGGCCAGG CAAAACGAACAAAAGGTAAAGAAGCAAGGAGCAATTGAATTTGGCGAGAGCCACTATCCGTATATCATTACGATGCATAT CCTTTTTTTCCTGTCCTTAATTGCCGAGGTGCTGCTGATGAATAAACAGCCGTCCAGCTGGTGGCTCGGTATCGCTGCAG TGATTTTAAGCGTACAGATCGTACGGTATTGGGCGCTTTGTTCCTTAGGAGCATATTGGAATACGAAAATCCTTGTTGTTCCAGGTGTAGAGCTTGTAAAAAAAGGTCCATATAAATGGATGAAACATCCAAACTATGCCGTTGTTATCCTCGAAATTTT GCTGATTCCGCTGCTTTATCAAGCATACGTCACCATGTGTCTGTTTTCCATTTTCAATGCCGTGTTGTTAAGCGTCAGAA TTCGCGCAGAgGACAAAGCATTACAGGAATACAGCGTAAAATAGaagaagaagtgtgaaaaagcgcagctgaaatagctg cgcttttttgtgtcataa SEQ ID NO: 3: Gramicidin S BGC ATCGATCGGCAGGTGATGTCAATAACACCTGCATCGGGAAGAATAAAGGGAGAGGTGAATGTGACTTTTATTTCACAAGT AAATAAATGGTTTGTTAATGCTAATGTTAACTCAGCTGCAAAGCTTAGGCTATTCTGTATTCCATATGCAGGCGGTGGTG CTTCCGCCTTTTATGAATGGAGTCATTTTTTTCCAAAGGAAATTGAAGTTTGTTCAATTCAATTACCTGGAAGGGAAAAT AGGGGGGCGGAAGTTCCGCTAACAAATTTACAACAGATAGTAGAAATAGTAGCTGAGGAAATACAACCATTAATAAATAT TCCATTTGCTTTTTTGGGGCATAGCATGGGAGCATTAATAAGTTTTGAACTGGCTCGCACAATACGGCAAAAGAGTAATG TTAATCCGGTTCACTTGTTTGTTTCAGGGCGACATGCACCTCAAATCCCATGTGCAAAACAAGACTATCATTTACTTCCC GATGAACAATTTATACAAGAATTGCGTTCATTGAATGGAACTCCAGAGATAGTATTACAAGACGCAGAGATGATGAGTAT ATTACTCCCAAGACTTCGGGCTGATTTTTCTGTGTGTGGCTCCTATCAGTACAAAAACGACGAGCCTTTTGAATGCCCAATCACTGCTTTTGGAGGAAAAAATGATAATGGTGTTACTTATCAATCATTAGAAGCCTGGAGAGAGCAAACCAAGAGGGAA TTTTCTGTGTGTATGTATCCAGGTGATCATTTTTTTCTTTACGAAAGCAAATATGAAATGATTGAGTTCATGTGTAAACA ATTACGTTTAGTATTAGCTCCTAAAATATAAggcctTGAtggccATCGAGAGACCAATAATAATAGGTCTCAGGAACTAT TTTTTACAGGGGGTATATatgTTAAACAGTTCTAAAAGTATATTGATTCATGCTCAAAATAAAAATGGAACGCATGAAGA GGAGCAGTATCTCTTTGCTGTGAACAACACCAAAGCGGAGTATCCACGTGATAAGACGATCCATCAGTTATTTGAgGAGC AGGTTAGTAAGAGgCCAAACAATGTAGCCATTGTATGTGAAAATGAGCAACTTACCTACCATGAGCTTAATGTGAAAGCC AATCAACTAGCACGGATTTTTATAGAAAAAGGGATTGGAAAAGACACTCTTGTTGGAATTATGATGGAGAAATCTATCGA TTTATTTATAGGCATATTAGCCGTTTTAAAAGCtGGTGGAGCATATGTTCCGATTGATATTGAATATCCTAAGGAAAGAA TTCAATATATTCTTGATGATAGTCAGGCAAGAATGCTACTTACCCAGAAGCATTTGGTTCATTTAATTCATAATATTCAA TTTAATGGGCAAGTGGAAATTTTTGAAGAAGATACTATCAAAATTAGAGAGGAACTAATCTACATGTACCAAGTAAATC AACCGATCTTGCTTATGTTATTTATACTTCTGGTACAACAGGCAATCCAAAAGGTACAATGCTGGAGCATAAAGGAATAA GTAATCTAAAGGTATTTTTCGAAAATAGTCTTAACGTGACTGAAAAGGATAGAATTGGTCAATTTGCCAGCATCTCTTTTGATGCATCTGTATGGGAGATGTTTATGGCTTTGTTAACGGGGGCTAGCCTGTATATTATCCTGAAGGATACAATCAATGA TTTTGTGAAGTTTGAACAATACATTAACCAAAAGGAAATCACTGTTATTACGTTACCACCTACCTATGTAGTTCATCTTG ATCCAGAACGTATTTTATCGATACAAACGTTAATTACAGCAGGCTCAGCTACCTCGCCTTCCTTAGTAAACAAGTGGAAG GAGAAAGTAACTTACATAAATGCCTATGGCCCTACGGAAACAACTATTTGTGCGACTACATGGGTAGCCACCAAAGAAAC AATAGGTCATTCAGTTCCAATCGGAGCACCAATTCAAAATACACAAATTTATATTGTCGATGAAAATCTTCAATTAAAAT CGGTTGGTGAAGCTGGTGAATTGTGTATTGGTGGAGAAGGGTTAGCAAGGGGATATTGGAAGCGACCGGAATTAACTTCC CAGAAGTTCGTTGATAACCCGTTTGTTCCAGGAGAGAAGTTGTATAACAGGAGATCAGGCAAGATGGCTATTCTGATGG AAATATTGAATATCTCGGAAGAATAGATAACCAGGTAAAGATTAGAGGTCACCGAGTTGAACTAGAAGAAGTTGAGTCTA TTCTTCTAAAGCATATGTATATTAGCGAAACTGCAGTAAGTGTGCATAAAGATCACCAAGAACAGCCGTATTTGTGCGCT TATTTTGTATCGGAAAAGCATATACCACTAGAACAGTTAAGACAATTCTCATCAGAAGAACTGCCAACGTATATGATCCC TTCTTATTTTATCCAGTTAGACAAAATGCCGCTTACATCAAATGGGAAGATTGATCGAAAGCAGTTGCCGGAACCTGATT TAACTTTCGGGATGAGGGTAGACTATGAAGCGCCGCGAAATGAAATCGAGGAAACGCTTGTTACTATCTGGCAGGATGTATTAGGTATTGAGAAAATCGGTATTAAAGATAATTTCTATGCATTAGGTGGAGATTCTATTAAAGCAATACAGGTTGCTGC TCGCCTGCATCCTCACCAAATTAAAGCTAGAACAAAAGATTTATTAAAGTATCCAACAATCGATCAACTCGTTCATTATA TAAAAGATAGTAAAAAGAAGAAGTGAGCAAGGTATTGTGGAAGGTGAGATTGGACTTACACCTATTCAGCATTGGTTCTTT GAACAACAATTTACAAATATGCACCATTGGAACCAATCGTATATGTTGTATACCAAATGGGTTTGATAAAGAGATCTT GCTAAGGGTATTTAATAAAATTGTTGAGCATCATGATGCATTACGTATGATATACAAACATCATAACGGAAAAGATCGTGC AGATAAATCGGGGGCTTGAAGGTACGTTGTTTGATTTTTATACCTTTGATTTAACTGCAAATGATAATGAGCAACAGGTG ATTTGTGAAGAATCTGCTCGATTACAAAATAGTATAAACTTGGAAGTAGGCCCTCTTAGAAAGATAGCGTTTCATAC TCAGAATGGAGATCACCTGTTTATGGCTATTCATCATTTGGTTGTGGATGGATTTTCTTGGAGGATTTTGTTTGAGGATT TGGCCACACAGCTTATGAACAAGCAATGCATCAGCAAACGATTGCTTTACCAGAGAAAACAGATTCATTTAAGGACTGGTCT ATTGAATTAGAAAAATATGCGAACAGCGAATTATTCCTAGAAGAAGCTGAATATTGGCATCATTTGAATTATTATACCGA GAACGTTCAAATTAAAGAAAGATTATGTCACCATGAACAATAAACAAAAGAATATACGTTATTAGGAATGGAGTTAACAA TAGAAGAGACAGAAAAATTATTGAAAAAATGTAAATAAAGCGTATCGAACAGAAATTAATGATATTTTATTAAACGGCACTTGGCTTTGCACTCAAAGAATGGGCCGATATTGATAAAATTGTAATTAACTTAGAGGGACACGGACGGGAAGAAATACTGGA ACAGATGAACATTGCAAGGACGGTAGGCTGGTTTACTTCCCAGTATCCTGTTGTACTTGATATGCAAAAATCGGATGATT TGTCTTATCAAATCAAATTAATGAAAGAAAATTTACGCAGAATACCTAACAAAGGAATCGGATATGAAATTTTTAAGTAT TTAACAACTGAATATTTACGGCCTGTTTTACCCTTTACATTAAAGCCGGAAATTAACTTTAACTACTTAGGACAGTTCGA TACGGACGTGAAaACTGAATTGTTTACTCGTTCTCCTTATAGCATGGGTAATTCATTAGGACCAGATGGAAAAAAATAATT TAAGCCCAGAAGGGGAAAGTTATTTTGTACTCAATATTAATGGTTTTATTGAAGAAGGTAAGCTTCACATCACCTTTTCT TATAATGAACAGCAGTATAAGGAGGATACCATTCAGCAATTGAGCCGGAGCTATAAGCAACATCTTTTGGCCATCATTGA ACATTGTGTACAGAAGGAAGATACTGAGTTAACTCCAAGTGATTTCAGTTTCAAGGAACTTGAATTAGAAGAGATGGATG ATATTTTCGATTTGTTGGCCGATTCATTAACGtaaggcctCGAtggccATCGATGTCTTCTTATTATTATGAAGACATGG AACATTATTATGAGGTGCTAGCATGAGTACATTTAAAAAAAGAACATGTTCAGGATATGTATCGTTTATCTCCCATGCAGG AAGGCATGTTGTTTCACGCATTACTTGATAAAGATAAAAATGCTCACCTGGTACAAATGTCTATCGCGATCGAAGGTATC GTGGATGTGGAGCTGCTTAGTGAAAGCTTGAACATATTGATTGATAGATACGATGTGTTTAGAACAACATTCTTACATGAAAAAATTAAACAACCGCTTCAGGTAGTGCTAAAGGAACGGCCTGTTCAGCTTCAATTTAAAGACATATCATCCTTAGATG AAGAAAAAAGAGAACAGGCTATTGAGCAGTATAAGTATCAAGATGGGGAAACAGTCTTTGATTTAACAAGAGATCCCTTG ATGAGAGTAGCTATTTTTCAAACTGGTAAGGTTAACTACCAAATGATCTGGAGCTTTCCACCATATTTTAATGGATGGTTG GTGCTTCAACATTATATTTAATGACTTGTTCAAATATATATCTGTCATTAAAAGAGAAGAAACCTCTTCAGTTAGAGGCGG TGCAACCATATAAGCAGTTTATTAAGTGGCTTGAAAAACAAGATAAACAGGAAGCaCTTCGCTACTGGAAAGAACATTTA ATGAATTATGATCAATCAGTAACATTACCTAAAAAGAAAGCAGCTATTAATAATACTACATATGAACCAGCACAGTTTCG TTTTGCGTTTGACAAAGTGCTTACCCAGCAGCTGCTTCGTATTGCCAATCAAAGCCAAGTAACACTAAATATTGTTTTTC AAACAATATGGGGGATTGTACTTCAAAAATACAATTCCACTAATGATGTTGTATATGGCTCTGTTGTATCAGGCCGTCCT TCTGAAATATCGGGAATTGAGAAAATGGTTGGACTATTTATTAATACTCTTCCATTACGTATCCAAACGCAAAAAGATCA ATCATTTATTGAATTAGTAAAGACTGTTCATCAAAACGTCCTTTTCTCGCAACAGCATGAGTATTTTCCATTGTATGAAA TACAAAATCATACAGAATTAAAACAGAATCTGATTGATCATATTATGGTAATTGAAAATTATCCTTTAGTAGAAGAATTG CAAAAGAATAGTATCATGCAAAAAGTAGGGTTTACAGTTCGTGATGTCAAAATGTTTGAACCAACTAATTATGATATGACAGTTATGTGTTTTACCTCGTGATGAAATTAGTGTCCGACTCGATTATAACGCAGCCGTTTATGATATAGATTTCATAAAAA AAATTGAAGGTCACATGAAAGAAGTGGCTTATGCGTGGCAAATAATCCACATGTGTTAGTACAGGACGTTCCTCTGCTT ACAAAGCAAGAAAAACAACATTTATTGGTAGAGCTGCATGATTCGATAACAGAGTATCCTGATAAAGACGATTCATCAGTT ATTTACAGAACAGGTAGAAAAAACACCAGAGCATGTGGCAGTTGTATTCGAAGATGAGAAAGTGACCTATAGAGAGCTGC ATGAGAGATCTAATCAATTAGCCAGATTCTTAAGAGAAAAGGCGTAAAAAAAGAAAGCATCATAGGCATTATGATGGAG CGTTCAGTTGAAATGATTGTTGGGATCTTAGGGATTTTAAAAGCTGGTGGAGCTTTTGTGCCTATTGATCCTGAATATCC AAAAGAAAGAATCGGCTATATGTTAGATTCTGTACGGCTAGTACTTACACAACGCCATTTAAAGGATAAATTTGCTTTTA CGAAAGAAACGATAGTAATTGAAGATCCAAGTATTTCACACGAGTTAACTGAAGAAAATAGATTATATTAATGAATCAGAG GACTTGTTTTATATTATTTATACATCAGGAACAACAGGTAAACCAAAAGGGGTTATGCTAGAGCACAAAAACATCGTTAA TCTGCTTCATTTTACTTTCGAGAAAACAAATATCAACTTTAGTGACAAAGTATTACAGTATACAACATGCAGTTTTGACG TGTGTTACCAAGAAATTTTTTCGACGCTCTTGTCTGGAGGGCAATTATATCTTATTAGGAAAGAAACTCAACGCGATGTA GAGCAATTATTTGATTTAGTAAAACGTGAAAATATTGAAGTATTATCCTTTCCTGTGGCTTTTCTAAAATTTATTTTCAATGAAAGAGAATTTATCAATCGTTTTCCAACTTGCGTGAAACATATTATCACAGCAGGAGAACAATTAGTAGTTAACAATG AGTTTAAACGTTATTTGCATGAACATAACGTACATTTACACAATCATTATGGTCCATCAGAAACGCATGTTGTTACCACC TATACTATTAATCCTGAAGCTGAAATTCCTGAATTACCACCGATAGGAAAACCTATCTCCAATACATGGATTTATATTTT GGATCAAGAACAACAACTACAACCACAAGGAATTGTAGGAGAGTTATATATTTCGGGCGCAAATGTTGGAAGAGGATATT TGAATAATCAAGAATTAACGGCAGAAAAATTCTTTGCAGATCCCTTTAGGCCAAACGAACGGATGTACCGAACAGGGGAT TTAGCAAGGTGGTTGCCAGACGGAAATATCGAATTTTTAGGAAGgGCCGATCATCAGGTGAAAATTAGGGGGCATCGAAT AGAGCTTGGTGAGATCGAGGCACAATTATTAAATTGTAAGGGTGTAAAAGAAGCTGTTGTTATCGATAAAGCGGATGATA AAGGCGGAAAATATTTATGTGCCTATGTTGTTATGGAAGTAGAAGTAAATGACTCTGAGCTTCGAGAATATTTGGGGAAA GCTTTGCCTGATTATATGATCCCGTCGTTCTTTGTTCCGTTGGATCAGCTGCCGCTTACACCAAACGGAAAAATAGACAG AAAATCTCTTCCGAATCTAGAGGGGATTGTGAATACAAACGCAAAATATGTAGTACCTACAAATGAGCTGGAAGAAAAAT TGGCTAAAATCTGGGAAGAAGTACTTGGGATTTCTCAGATCGGTATACAAGACAATTTCTTTTCGTTAGGCGGGCATTCT CTTAAAGCCATTACGCTTATTTCCCGTATGAACAAAGAGTGTAATGTAGACATTCCTCTACGTTTGTTATTTGAAGCACCAACCATTCAGGAAATCTCTAATTATATAAACGGGGCAAAGAAAGAAAGCTATGTTGCCATTCAGCCTGTACCAGAACAAG AGTACTATCCTGTATCATCAGTTCAAAAAAGAATGTTTATTCTTAATGAATTTGATCGTTCAGGTACGGCCTATAATTTA CCTGGTGTTATGTTTCTAGATGGAAAATTGAACTACCGACAATTGGAAGCAGCGGTAAAAAAAATTAGTTGAGCGACATGA AGCGCTGCGTACTTCCTTTCATTCAATTAATGGGGAACCAGTTCAGCGGGTGCATCAAAATGTAGAACTGCAGATTGCTT ATTCAGAGTCAACGGAAGATCAGGTGGAGCGAATTATTGCGGAATTTATGCAACCATTTGCTCTTGAAGTTGCTCCGTTA CTTCGTGTAGGTCTTGTTAAATTGGAGGCAGAACGTCATCTATTTATAATGGATATGCATCATATCATCTCGGATGGGGT ATCCATGCAGATCATGATTCAAGAAATTGCTGATTTGTATAAAGAAAAGGAACTTCCTACGTTAGGCATTCAATATAAAG ACTTTACTGTTTGGCATAATCGCTTGCTTCAATCGGATGTTATTGAAAAACAAGAAGCTTACTGGCTGAACGTATTTGCA GAAGAGATTCCAGTATTGAATCTACCGACCGATTACCCAAGACCAACCATTCAAAGCTTTGATGGTAAAAGATTTACATT CAGTACAGGAAAGCAGCTTATGGATGATTTATACAAGGTGGCAACAGAAACAGGAACAACACTATATATGGTTTTACTTG CTGCGTATAATGTTTTCTTATCGAAGTATTCCGGGCAAGATGACATCGTTGTAGGAACACCGATTGCTGGTAGGTCcCAT GCTGATGTGGAAAATATGCTGGGGATGTTTGTAAATACATTAGCAATAAGAAGTCGTTTAAATAATGAGGATACTTTTAAAGATTTTTTAGCAAATGTAAAACAAACGGCTTTGCATGCCTATGAAAATCCAGATTACCCATTTGATACGCTTGTCGAAA AGTTGGGTATACAGAGAGATTTAAGTAGAAATCCATTATTTGATACGATGTTTGTTTTGCAAAATACGGATAGAAAGTCT TTTGAGGTTGAACAGATAACGATTACACCATATGTTCCAAATAGCAGACATTCTAAATTTGATCTTACATTAGAGGTTAG CGAAGAACAAAATGAGATTTTATTATGCCTAGAATATTGCACTAAATTATTTACGGATAAAACAGTTGAAAGAATGGCTG GTCATTTTTTACAGATCTTGCATGCAATTGTTGGGAACCCAACGATTATAATATCAGAAATCGAGATATTGTCTGAAGAA GAAAAACAACATATTTTATTCGAGTTCAACGATACGAAAACCACATATCCACATATGCAAACAATTCAAGGATTATTTGA GGAACAGGTGGAGAAaACGCCCGACCATGTTGCAGTTGGATGGAAAGACCAAACATTAACGTATCGGGAACTTAACGAAA GAGCGAATCAGGTCGCAAGAGTCTTACGGCAAAAAGGAGTCCAACCCGATAATATCGTGGGATTGCTGGTTGAGCGTTCA CCTGAAATGCTCGTGGGTATCATGGGAATTCTTAAAGCAGGGGGAGCTTATTTACCTCTTGATCCGGAGTACCCAGCGGA TAGAATTTCGTACATGATACAAGATTGTGGTGTACGCATTATGCTTACCCAACAGCATCTTTTATCTTTAGTACATGATG AATTTGATTGTGTTATTTTGGATGAgGACAGTTTGTACAAGGGGGATTCTTCCAATTTGGCTCCGGTTAACCAGGCCGGG GATTTAGCCTACATCATGTACACTTCTGGTTCTACAGGAAAGCCTAAAGGTGTTATGGTAGAACATCGAAATGTGATTCGCCTTGTGAAAAATACAAATTATGTTCAGGTCCGCGAgGACGATCGTATAATACAGACCGGAGCAATTGGATTCGATGCAC TGACATTTGAAGTTTTTGGCTCATTGCTGCATGGAGCTGAATTGTATCCTGTTACTAAAGACGTGCTATTAGATGCAGAG AAACTACACAAATTTTTACAAGCGAATCAAATTACGATTATGTGGTTAACTTCTCCGTTATTTAACCAATTGTCACAAGG AACCGAAGAGATGTTTGCTGGCCTTCGCTCCCTAATTGTAGGTGGAGATGCCTTGTCTCCGAAACACATCAATAATGTAA AGCGAAAATGCCCTAATCTGACTATGTGGAACGGTTACGGCCCAACAGAAAACACCACTTTTTCTACATGCTTTCTTATT GATAAAGAATATGATGACAATATTCCGATAGGGAAGGCCATTAGTAATTCAACAGTGTATATCATGGACCGGTATGGCCA GCTTCAGCCGGTGGGTGTACCAGGAGAATTATGTGTAGGAGGGGATGGGGTTGCCAGGGGATATATGAATCAGCCTGCAT TAACAGAAGAGAAGTTTGTCCCAAATCCATTCGCTCCTGGTGAGAGAATGTATCGCACGGGGGATTTGGCAAGATGGTTG CCTGATGGAACAATTGAGTATTTAGGTCGTATTGATCAGCAaGTGAAAATCAGGGGCTACCGTATTGAACCGGGAGAGAT TGAAACGCTTCTTGTGAAGCACAAAAAAGTCAAAGAATCGGTAATCATGGTAGTAGAGGATAATAATGGACAAAAGGCTC TATG CGCTTATTACGTTCCGGAAGAAGAAGTAACGGTATCTGAACTGAGGGAATATATAGCTAAAGAGTTGCCTGTTTAC ATGGTTCCAGCCTATTTTGTACAGATTGAACAAATGCCTCTTACACAGAACGGTAAAGTAAATCGAAGCGCGTTACCAAA ACCAGATGGTGAATTTGGTACAGCAACCGAATATGTAGCGCCTAGCAGCGACATTGAAATGAAGCTGGCAGAGATTTGGCA TAATGTGTTAGGGGTAAACAAAATCGGGGTACTGATAACTTCTTTGAATTAGGTGGTCATTCATTAAGAGCTATGACAA TGATTTCCCAGGTACATAAAAGGAGTTCGACGTTGAATTGCCATTATTGAAAAGGAATGTACCTGGCCATTCAACCTGTTACCCCGCAGGATTACTATCCAGTATC ATCTGCGCAAAAAGGAGGATGTACATCCTTTATGAATTTGAGGGGGCTGGCATTAACCTATAATGTACCTAATGTAATGTAATGTATAGTATAGGAAGGAAAGCTGGATTACCTTTGAATAAGCTGAAAAGTTTGGTTAAAAAAGTTTGGTTAAAATCGACATAGGGCGCTTCGAACGTCT TTCTATTCGCTTAATGGGAGAACCAGTTCAGCGGTTACATCAAAAATGTAGAGCTACAGATTGCTTATTATTGGGAAGAGCAGAAGA AGATGAGATAGAGCAAATTGTAGAAAGCTTTGTTCAACCATTTGACCTTGAAATAGCTCCGCTTGCTCGCGTAGGGCTTG TTAAATTGGCATCGGATCGCTTATTCCTAATGGATATGCATATTATCTCAGATGGTGTATCAATGCAAATTATA ACAAAGAAATTGCCGACTTATATAAAGGAAAAGAGCTTGCTGAACTGCATATTCAGTATAAAGATTTTGCTGTATGCA AAACGAATGGTTTCAATCTGACGCTTGAAAAACAGAAAAGGTATTGGTTGAACACCTTGCAGAGGATATTCCGGTTT TAAATTTGTCAACTGATTATCCAAGACCGACAATTCAAAGTTTTGAAGGAGATAATTGTCACGTTTAGTGCAGGGAAGCAACTTGCGGAAGAATTGAAACGCCTGGCTGCAGAAACAGGGACGACTTTGTATATGCTTCTGTTAGCGGGCGTACAATGTACT TTTACACAAATACTCGGGACAGGAAGAAATTGTAGTAGGAACGCCTATTGCCGGGCGATCTCACGCAGATGTGGAAAATA TTGTTTGGGATGTTGTCAATACGCTTGCATTGAAAAATACCCCTATAGCCGTACGCACCTTCCACGAATTCCTGTTGGAA GTAAAACAAAATGCTTTAGAAGCTTTTGAAAATCAAGACTATCCATTTGAAATTTGATAGAGAAGCTGCAAGTGCGTCG CGACTTAAGTCGCAATCCATTATTTGATACAATGTTTAGCCTAAGCAAATTGACGAACAAGTAGATAGGATTGAGG GATTGAACTTCAGCCCATATGAAATGCAGTATTGGATTGCAAAATTTGATTCATTCGATAATTTTAGTAGAAAAAGCAAG GAT GACATTCAATTTTATTTTAACTATTGCACGAATCTGTTTTAAAAAAGAAACGATAGAACGATTAGCGACACACTTTATGCA TATTTTACAGGAGATTGTTATTAATCCTGAGATTAAGTTATGTGAAATTAATATGCTGTCCGAAGAAGAACAGCAGCGTG TCCTGTATGACTTTAATGGCACAGATGCAACCTACGCTACGAATAAAATATTCCATGAGTTATTTGAAGAACAGGTTGAA AAAACACCAGATCATATGCGGTGATAGATGAAAGAGAAAAGCTTTCCTATCAGGAGCTTAATGCGAAAGCGAATCAGCT GGCACGAGTGCTGCGCCAAAAAGGACAGCCTAATAGCATGGTAGGTATTATGGTAGATCGCTCACTCGACATGATT TAGGAATGCTTGGGGTTTAAAAGCAGGAGGAGCATATGTGCCTATCGATATAGACTATCCTCAGGAACGGATTAGCTACATGATGGAAGATAGTGGTGCAGCGCTCTTGTTAACACAACAAAAGTTGACACAGCAAATTGCGTTTTCTGGTGACATTTT GTATCTTGACCAAGAAGAATGGCTTCATGAGGAAGCTTCAAATTTAGAACCCATCGCTCGTCCGCAGGATATAGCCTATA TCATTTACACTTCTGGTACAACCGGAAAGCCAAAAGGTGTGATGATTGAGCATCAAAGCTATGTGAATGTAGCAATGGCA TGGAAAGATGCCTATCGGTTAGATACATTCCCGGTCCGTTTGCTTCAGATGGCTAGCTTTGCCTTTGACGTATCTGCgGG TGATTTTGCCAGAGCACTACTTACAGGTGGGCAATTAATTGTATGTCCAAATGAAGTAAAGATGGACCCAGCTTCTTTAT ATGCCATTATTAAGAAATATGACATTACTATTTTTGAAGCAACGCCTGCTCTAGTGATTCCATTGATGGAGTATATTTAT GAACAGAAGCTGGATATTAGCCAGTTACAGATTCTGATTGTCGGATCGGACAGTTGTTCGATGGAgGACTTTAAAACCTT GGTTTCCCGTTTTGGTTCAACTATACGTATTGTGAATAGCTATGGAGTAACCGAAGCGTGCATTGATTCTAGCTATTATG AACAACCGCTTTCTTCGTTACATGTAACAGGAACTGTACCGATTGGAAAACCGTACGCTAACATGAAAATGTATATTATG AATCAATATTTGCAGATTCAGCCTGTAGGTGTAATTGGAGAATTATGTATTGGAGGAGCCGGGGTTGCCCGTGGATATTT AAATAGACCGGACTTAACAGCAGAAAAGTTTGTCCCTAATCCTTTTGTTCCAGGTGAAAAGCTGTATCGAACAGGCGACT TGGCAAGATGGATGCCGGATGGGAATGTTGAGTTTCTTGGTCGAAATGACCATCAGGTGAAAATCAGAGGGATTCGAATCGAGCTTGGAGAAATCGAAGCACAACTGCGTAAACATGATAGCATAAAAGGCAACTGTGATCGCAAGAGAAGATCACAT GAAAGAGAAATTTATGTGCGTATATGGTGACCGAAGGAAGTAAATGTAGCTGAACTGCGTGCGTATCTAGCAAATG ATCTGCCTGCGGCAATTCCGTCATATTGTATCGCTCGAAGCAATGCCACTTACTGCTAATGGAAAAATTGATAAG CGATCTTTACCAGAGCCCGATGGTTCCATATCGATAGGAACAGAATATGTAGCTCCGCGTACCATGCTTGAGGGAAACT AGAAGAGATATGGAAAGATGTATTGGGTTTACAGCGTGTTGGCATTCACGATGACTTCTTTACAATAGGTGGCCATTCAT TGAAGGCTATGGCTGTTATTTCGCAAGTTCATAAAGAATGCCAGACTGAAGTTCCTCTGCGTGTCTTTTGAAACACCT ACCATTCAAGGACTGGCTAAATATAGAGGAaACGGACACAGAGCAATATATGGCTATTCAGCCGGTTAGCGGACAGGA CTATTATCCAGTATCATCAGCAAAAGAATGTTTATTGTCAATTTGATGGAGTAGGAATTAGCTACAATATGC CTTCCATCATGCTGATTGAAGGAAAACTTGAGCGAACACGCTTGGAATCAGCATTTAAAAGATTGATAGAACGACATGAG AGCCTTCGAACATCTTTGAAATAATAATGGTAAGCCTGTACAAGATTCATGAGGAAGTTGATTTCCAATATGTCCTA TCAGGTGGCTTCTAATGAACAAGTAGAGAAGATGATCGATGAGTTCATTCAGCCTTTCGATTTAAGTGTTGCACCGCTGC TTCGTGTGGAACTTTAAATTGGAAGAgGACCGTCATGTGCTTATATTTGATATGCATCATATTCTCAGATGGTATATCTTCCAATATTTTGATGAAAGAATTAGGAGAACTATATCAAGGTAATGCTTTACCAGAACTTCGTATTCAATACAAGGA TTTCGCTGTATGGCAAAATGAGTGGTTCCAGTCAGAAGCCTTTAAAAAGCAAGAAGAATACTGGGTAAATGTtTTCGCAG ATGAACGCCCGATTCTGGATATACCGACGGATTATCCAAGGCCGATGCAACAAAGCTTTGATGGTGCTCAACTTACATTT GGAACCGGAAAGCAGCTTATGGATGGGTTATACAGGGTAGCAACGGAAACGGGAACAACGCTTTATATGGTTTTGCTTGC GGCATATAATGTTCTTCTTTCCAAATATTCTGGTCAAGAAGATATTATTGTAGGGACACCGATTGTGGGTAGATCCCATA CTGACCTTGAGAATATTGTCGGGATGTTTGTCAACACGTTAGCAATGAGAAATAAACCGGAAGGAGAAAAGACGTTCAAA GCATTTGTATCAGAAATAAAGCAGAATGCACTAGCGGCTTTTGAGAATCAGGATTATCCATTTGAgGAGCTTATCGAAAA ACTAGAGATACAAAGGGACTTAAGCAGAAATCCATTATTTGATACGCTCTTTAGCCTTCAAAACATAGGTGAAGAATCAT TTGAACTAGCCGAATTAACATGCAAACCTTTCGATTTGGTAAGCAAATTAGAGCATGCCAAGTTTGATCTGAGTCTTGTG GCAGTAGAAAAAGAGGAAGAAATTGCATTTGGGCTTCAATACTGCACAAAACTGTATAAGGAAAAAACAGTTGAACAACT GGCTCAACATTTTATTCAAATAGTAAAAGCAATTGTAGAAAATCCAGATGTCAAATTATCTGATATTGATATGTTATCTG AAGAAGAGAAGAAACAAATCATGCTTGAGTTCAATGATACGAAAATACAATATCCGCAGAATCAAACAATACAGGAATTGTTTGAgGAGCAAGTGAAGAAAACACCTGAACATATAGCAATCGTATGGGAAGGGCAAGCATTAACCTATCATGAGCTAAA TATAAAAGCTAATCAGTTAGCTCGTGTATTACGAGAAAAAGGGGTAACCCCTAATCATCCTGTAGCGATTATGACGGAAC GCTCATTAGAGATGATCGTAGGTATCTTTAGTATTTTGAAAGCAGGAGGAGCATATGTTCCAATTGATCCAGCCTATCCA CAAGAACGTATTCAATAACTTGCTTGAGATAGCGGAGCGACGCTACTGCTTACTCAGTCACATGTATTAAATAAATTACC GGTCGATATCGAATGGTTGGATCTTACAGATGAACAAAACTATGTAGAAGATGGTACCAATCTTCCATTTATGAATCAGT CAACAGATCTTGCCTATATTATTTATACATCCGGTACAACAGGCAAGCCTAAAGGGGTTATGATTGAACATCAAAGCATC ATCAACTGCCTGCAATGGCGGAAGGAAGAATACGAATTTGGACCAGGGGATACGGCTCTACAAGTGTTTTCCTTTGCTTT TGATGGATTTGTAGCAAGTTTGTTTGCTCCGATTCTTGCtGGTGCAACGTCTGTTCTCCCTAAGGAGGAAGAAGCAAAAG ATCCAGTTGCATTGAAAAAACTGATCGCATCAGAAGAGATTACACATTACTACGGTGTGCCTAGTTTGTTTAGTGCCATT CTTGATGTTTCTTCTAGTAAGGATTTGCAAAATTTACGCTGCGTCACTTTGGGAGGAGAGAAATTACCGGCTCAAATTGT TAAAAAAATCAAAGAAAAAAATAAAGAAATTGAAGTCAACAACGAATATGGGCCTACTGAAAATAGTGTAGTAACTACTA TTATGCGCGATATACAGGTAGAACAAGAGATTACTATTGGTCGCCCATTATCTAACGTAGATGTATATATTGTCAATTGTAATCATCAATTACAACCAGTAGGTGTAGTAGGGGAATTATGTATTGGTGGACAGGGACTTGCAAGAGGATATTTGAATAA ACCAGAGCTTACAGCAGATAAATTTGTTGTAAATCCATTCGTACCTGGTGAACGTATGTACAAAACCGGTGACCTTGCAA AATGGCGCTCAGATGGAATGATTGAATATGTGGGGCGTGTGATGAACAAGTAAAAGTAAGAGGATATCGGATTGAGCTT GGTGAAATTGAATCAGCTATCTAGAATACGAAAAAATTAAAGGAAGCGGTAGTTATGGTTTCGGAGCATACTGCATCTGA ACAGATGTTATGTGCTTATATTGTAGGGGAAGAGATGTACTGACTCTGGACTTAAGAAGCTATCTAGCAAAATTACTAC CAAGTTATATGATTCCAAACTATTTTATCCAATTGGATAGTATTCCGCTTACACCAAACGGTAAAGTGGATCGTAAAGCA TTGCCTGAACCTCAAACCATTGGCTTAATGGCAAGGGAGTATGTTGCACCAAGGAATGAAATCGAAGCACAGCTAGTACT CATTTGGCAAGAGGTATTAGGAATAGAACTGATCGGTATTACCGATAATTTCTTTGAAATTAGGAGGGCATTCTTTAAAGG CAACGCTTTTAGTTGCAAAAATTTACGAGTACATGCAAATAGAGAGAGAAAATAATGTACATCAGCCTATTTTGGTAAATGTAGAAGCAGA TAGAGAGGCGCTATCTCTTAACGGCGAGAAGCAAAGAAAAAATATAGAGCTACCTATTCTGCTAAAACGAAGAAAACAGATC GAAACGTATTCTGCTTCGCCCCATTGGTGCACAAAGGTGTTTTTATAAAAAAGCTTGCTGAACAAATCCCTACTGCATCCTTGTATGGCTTTGACTTCATTGAAGATGATGATCGAATTCAGCAATATATTGAATCGATGATTCAAACTCAGTCAGACGG ACAATATGTGCTAATTGGTTATTCTTCAGGAGGGAACCTGGCTTTTGAAGTAGCAAAAGAAATGGAAAGGCAAGGATATA GTGTATCTGATTTGGTCTTGTTCGATGTTTACTGGAAGGGAAAAGTaTTCGAGCAAACAAAAGAAGAAGAAGAAGAAAAC ATAAAAATAATAATGGAAGAATTAAGGGAAAATCCAGGAATGTTCAATATGACACGAGAGGATTTTGAACTGTATTTTGC GAATGAATTTGTGAAACAAAGTTTCACACGGAAAATGCGCAAATACATGAGTTTTTATACGCAGTTAGTTAATTATGGGG AAGTAGAAGCTACAATTCACCTTATACAAGCAGAATTTGAGGAAGAAAAAATTGACGAAAACGAAAAAGCCGACGAAGAA GAAAAAACATATCTAGAGGAAAAATGGAATGAAAAAGCATGGAACAAAGCAGCAAAAAGATTTGTAAAATATAACGGATA TGGCGCTCATTCTAACATGCTAGGAGGTGATGGTTTAGAGAGAAATTCCTCTATCCTTAAACAGATACTACAAGGGACAT TTGTAGTAAAATAAaagaagaagtgtgaaaaagcgcagctgaaatagctgcgcttttttgtgtcataa SEQ ID NO: 4: BBaK_780000 - PabrB AAGAAGAAGTGTGAAAAAGCGCAGCTGAAATAGCTGCGCTTTTTTGTGTCATAATCCTAATATATACATACGCCCTGAAA AAGAATAATTAAAATTAAAAATCTTTAATGAAAATAAAAAAAGTCTGTTCGTGTCGAATTTTGTCGTATATAATCAAATG AAATAAAAAACTTTGGTTCGAAAGTCTTGATTTAAAAGGATTTTTAGTAGGATAATAGCTTTATTAAATATTTATAAAATGCTGTTATTTCGGTAGTTTCCAAGACATTACTGACTATAAGAACTAATTCTTACAATCAATAGTAAACAAAATGATTGAC GATTATTGGAAACCTTGTTATGCTATGAAGGTAAGGAT Sequence number 5: BBaK_780000 - PvalS AAGAAGAAGTGTGAAAAAGCGCAGCTGAAATAGCTGCGCTTTTTTGTGTCATAATCCTAGATTAGGATTGCGAGCAGCAA AACATCAAAGGTTGTCGGAAAGAAAATGGTTCTGATTCCTTGAAAAATCGTAATGGGAATAATCACTTGTGCGGATACAA GCCGAATTTGCCTTACCCATGGCGGCAGCGAATAAGAGCTGAAACGTTTCTTCACGGTGCATCCTCCTCTACGCATTTAC AAGCATCATATGTAAACTTGGGCAATAGGTGCCTGCCCATCTGTATAGAAAGCGGTGTTTTTGGAAAAGATGATTGACGA ATCAAAAACACTTTTACTATAATAAAGAACATAAATAA Sequence number 6: BBaK_780000 - Phag AAGAAGAAGTGTGAAAAAGCGCAGCTGAAATAGCTGCGCTTTTTTGTGTCATAATCCTTGAAGTAAAAGTGATTGCGGTT GAAGGGGATCAAGTGAAGCTTGGAATTGACGCCCCAAAGCATATTGATATTCACAGGAAAGAAATTTACTTGACCATTCA GGAAGAAAATAACCGTGCAGCAGCGTTATCCAGCGATGTGATCTCCGCATTATCCTCACAAAAAAAGTGAGGATTTTTTT ATTTTTGTATTAACAAAATCAGAGACAATCCGATATTAATGATGTAGCCGGGAGGAGGCGCAAAAGACTCAGCCAGTTAC AAAATAAGGGCACAAGGACGTGCCTTAACAACATATTC Sequence number 7: BBaK_780000 - PspoVGAAGAAGAAGTGTGAAAAAGCGCAGCTGAAATAGCTGCGCTTTTTTGTGTCATAATCCTTGCGGAAGTAAACGAAGTGTAC GGACAATATTTTGACACTCACAAACCGGCGAGATCTTGTGTTGAAGTCGCGAGACTCCCGAAGGATGCGTTAGTCGAGAT CGAAGTTATTGCACTGGTGAAATAATAAGAAAAGTGATTCTGGGAGAGCCGGGATCACTTTTTTATTTACCTTATGCCCG AAATGAAAGCTTTATGACCTAATTGTGTAACTATATCCTATTTTTTCAAAAAATATTTTAAAAACGAGCAGGATTTCAGA AAAAATCGTGGAATTGATACACTAATGCTTTTATATAG Sequence number 8: BBaK_780000-PsrfAA AAGAAGAAGTGTGAAAAAGCGCAGCTGAAATAGCTGCGCTTTTTTGTGTCATAATCCTGACGCTCTTCGCAAGGGTGTCT TTTTTTGCCTTTTTTTCGGTTTTTGCGCGGTACACATAGTCATGTAAAGATTGTAAATTGCATTCAGCAATAAAAAAAGA TTGAACGCAGCAGTTTGGTTTAAAAATTTTTATTTTTCTGTAAATAATGTTTAGTGGAAATGATTGCGGCATCCCGCAAA AAATATTGCTGTAAATAAACTGGAATCTTTCGGCATCCCGCATGAAACTTTTCACCCATTTTTCGGTGATAAAAACATTT TTTTCATTTAAACTGAACGGTAGAAAGATAAAAAATAT Sequence number 9: BBaK_780000-Pcdd AAGAAGAAGTGTGAAAAAGCGCAGCTGAAATAGCTGCGCTTTTTTGTGTCATAATCCTTATTGAGTGGATGATTATATTC CTTTTGATAGGTGGTATGTTTTCGCTTGAACTTTTAAATACAGCCATTGAACATACGGTTGATTTAATAACTGACAAACATCACCCTCTTGCTAAAGCGGCCAAGGACGCTGCCGCCGGGGCTGTTTGCGTTTTTGCCGTGATTTCGTGTATCATTGGTT TACTTATTTTTTTGCCAAAGCTGTAATGGCTGAAAATTCTTACATTTATTTTACATTTTTAGAAATGGGCGTGAAAAAAA GCGCGCGATTATGTAAAATATAAAGTGATAGCGGTACC Sequence number 10: BBaK_780000 - PlytR AAGAAGAAGTGTGAAAAAGCGCAGCTGAAATAGCTGCGCTTTTTTGTGTCATAATCCTCTAACCCTACATAAGTACCTTC TTTTGTTTCAATGTTACTGTCTGGCGATACATCTTCACCTTGACTCTTTTGACTATTAACCCCGCAACCCGAAAGAAGCA ATATAAAGAACAGTAAAGCAATAAATTTTTTCATTTTTTTCACCTCATTATATTTTATCGTCAACCTATTTTATATTTTA AAGAAAAATTAAGAAACAATGAAACTTTTTTTTATAAAAAACGACTATTTTAGGATTTCATTCTTGTATTAAATAGAGTT GTATTTATTGGAAATTTAACTCATAATGAAAGTAATTT Sequence number 11: BBaK_780000 - Pveg AAGAAGAAGTGTGAAAAAGCGCAGCTGAAATAGCTGCGCTTTTTTGTGTCATAATCCTTATGGGAAGTGCTCCGTAATAC GCTGACAAGAGAGAAAGGGCTTGGAGGTATTGAAACAAGAGGAGTTCTGAGAATTGGTATGCCTTATAAGTCCAATTAAC AGTTGAAAACCTGCATAGGAGAGCTATGCGGGTTTTTTATTTTACATAATGATACATAATTTACCGAAACTTGCGGAACA TAATTGAGGAATCATAGAATTTTGTCAAAATAATTTTATTGACAACGTCTTATTAACGTTGATATAATTTAAATTTTATT TGACAAAAATGGGCTCGTGTTGTACAATAAATGTAGTG Sequence number12: BBaK_780000 - PmmgA AAGAAGAAGTGTGAAAAAGCGCAGCTGAAATAGCTGCGCTTTTTTGTGTCATAATCCTTCGATATATCGCGTCTATTCCG GCTTCCGGCTATCACCCGAAGATAAACAGCCCAGGGGTCACAGATGAAGTACTGAAGAAAATGAGGAACGGTTTGATTAA GGTAAGGCCGTATACAGTCAATCGTCCGGAAGATATGAAGCGTCTCATTGAAGCGGGAGCAGACGGCATGTTTACCGACT TTCCAGAAAAGGCTTCGGCATTGCTGAAAAATGAATAGTTGTTAGAAGGAGGCTGTTTGACGCAGCCTTCTTTTTTCATT CATTCATGCCCGTTTCAAAGCATACATTCATAGAAGAC Sequence number 13: BBaK_780000 - PyqfD AAGAAGAAGTGTGAAAAAGCGCAGCTGAAATAGCTGCGCTTTTTTGTGTCATAATCCTAGATGCCCCTGCACCTATCCCT AACCGTATGGAACAGGCAAGACGGGAAGCGGAAGAAAGACGCAGGGAAACAGCAAGAAACCTGAAAGGGCTGGAACGAGA TCTTGCTGCTGCCAAACAAAAAACAGTATACACAAAACAAAAAATGCTTCAGGTGAATAAAGACACCGTCGTACAGGGGA TCGTTCTAGGAGAGGTGTTCGGACCTCCACGGGCGAAAAAACCTCACCGTACGATGCGCCCGGCCCGTAAAAATTAAAGT GTTAGAACCTCCTTTCAAATCATACATATGAGATGAAA Sequence number 14: BBaK_780000 - PsigW AAGAAGAAGTGTGAAAAAGCGCAGCTGAAATAGCTGCGCTTTTTTGTGTCATAATCCTTGCCCCCCTCCACCATTATTGG GCTATAGCCAAGCGGTAAGGCAACGGACTTTGACTCCGTCATGCGTTGGTTCGAATCCAGCTAGCCCAGTCACAGACACCTTTGATCAAAAGGTGTCTTTTTTCTTTTCGGAAAAATCATTCCAACTTCTAACTGTTCAGTCTGTATAATAATTTTAAAA ATATGTTAAGGTAGTTTATTCACGAATTACCATCTACACCCTGCCAAAAATTTGATAAACTTATTTTATAAAAAAAATTGA AACCTTTTGAAACGAAGCTCGTATACATACAGACCGGT
Claims
1. A method for producing a strain having a desired property, comprising the steps of: 1) providing a construct comprising a gene cluster and a plurality of promoters; 2) creating a combinatorial library of the promoters in the construct; and 3) selecting a strain having the desired property in a host cell.
2. The method of claim 1, wherein the plurality of promoters are in a monocistronic arrangement for each gene contained in the gene cluster, in a polycistronic arrangement for all genes in the gene cluster, or in a mixed monocistronic and polycistronic arrangement for the genes in the gene cluster.
3. The method according to claim 1, wherein the strain having the desired property has at least one or more properties selected from the following properties: the ability to produce a target substance, the ability to highly produce a target substance, the ability to retain a target substance within the cell and not secrete it, the ability to secrete a target substance outside the cell, the ability to be easily cultured accompanied by the production of a target substance, the ability to produce multiple target substances in a desired ratio, the ability to produce a target substance without producing harmful substances, the ability to produce a robust amount of a target substance, the ability to prevent defects in a gene that produces a target substance during the culture period, the ability to control the production of a target substance, the ability to suppress the production of substances other than the target substance, the ability to suppress the production of by-products and / or impurities that are difficult to separate by affinity, ion exchange, gel filtration, reverse phase, normal phase, chiral chromatography, distillation, crystallization, or the like, the ability to produce a small amount of empty capsids in the production of a viral vector, and the ability to prevent defects in a plasmid.
4. A method for performing an action based on a desired property using a strain produced by the method of claim 1.
5. The method according to claim 1, further comprising: 4) creating a combinatorial library of constructs from one or more strains selected in step 3) and introducing the constructs into a host cell of interest; and 5) repeating step 3).
6. A method for producing a substance in a host organism, the method comprising: (A) constructing a construct in which a promoter introduction site and a sequence for reconstruction are added to a group of genes involved in the production of a substance from which undesired restriction enzyme recognition sequences have been eliminated; (B) introducing a plurality of constructs in which a promoter has been introduced into the promoter introduction site into a host organism for creating a combinatorial library; and (C) constructing a host organism for creating a combinatorial library from Combi-OGAB. TM (D) culturing a host organism for production having the constructs in the combinatorial library and selecting a plurality of strains based on an arbitrary criterion; (E) selecting the promoter sites in the constructs of the plurality of strains as Combi-OGAB. TM (F) producing a substance using a strain having desired properties.
7. The method of claim 6, wherein the combinatorial library host organism and the production host organism are the same.
8. The method of claim 6, wherein the combinatorial library host organism and the production host organism are different.
9. The method of claim 7, wherein the host organism is Bacillus subtilis.
10. A method for producing a substance in a host organism, said method comprising producing the substance with a strain produced according to the method of claim 1.
11. A method for producing a substance in a host organism, the method comprising the step of producing the substance with a strain obtained by steps (A) to (E) of the method according to claim 6.
12. The method of any one of claims 6 to 11, further comprising modifying the strain.
13. The method of claim 6, further comprising repeating steps (D) and (E) multiple times.
14. The construction of the construct in the step (A) is carried out using OGAB TM The method according to claim 6, which is carried out by the method.
15. The method according to claim 6, wherein the promoters are a plurality of promoters differing from each other in transcription initiation time and / or transcription strength.
16. The method of claim 6, wherein the production host organism is Bacillus subtilis, actinomycetes, filamentous fungi, yeast, hydrogen bacteria, Corynebacterium or an animal cell.
17. The method of claim 6, wherein the host organism is Bacillus subtilis.
18. The method of claim 6, wherein the unwanted restriction enzyme recognition sequences are Type IIS restriction enzyme recognition sequences selected from the group consisting of AarI, BsaI, BbsI, BsmBI, BspQI, and an SfiI recognition sequence for reconstruction.
19. The method of claim 6, wherein the sequence for reconstruction is an SfiI recognition sequence.
20. The method according to claim 6, wherein the gene group is a gene group of polyketide synthase (PKS) and non-ribosomal peptide synthase (NRPS).
Citation Information
Patent Citations
Double-stranded DNA synthesis method
JP2019198236A
Preparation method of unit DNA composition, and manufacturing method of DNA connected body
JP2021184730A
Spin sawing machine
JP2023095819A
Method for constructing a chimeric plasmid library
JP7101431B2
Multiplexed promoter engineering platform and method for manufacturing same
KR102301301B1
